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Abstract 
Ginseng has played a vital role in traditional Chinese medicine for thousands of years. There 
are 22 cultivars of ginseng including North American ginseng (Panax quinquefolius) and 
Asian ginseng (Panax ginseng). The use of North American ginseng has increased 
dramatically and there is a strong need to understand its immunomodulatory effects. This is 
because the majority of current research focusing on the Asian ginseng variant. Human 
peripheral blood mononuclear cells (PBMC) were used to test the immunomodulatory 
properties of 3 North American ginseng extracts, COLD-FX® and deglycosylated individual 
ginsenosides. Microarray analysis of PBMC exposed to the aqueous ginseng extract was used 
to determine the induced transcriptional profile. The aqueous ginseng extract induced a Th1 
transcriptional profile likely by modulating the MAPK (ERK-1/2), PI3K, p38 and NF-κB 
signalling pathways. The high molecular weight polysaccharides of North American ginseng 
induced the production of pro-inflammatory cytokines and decreased the adaptive T cell 
response to superantigen. These responses were antagonized by deglycosylated ginsenosides 
that also antagonized the induction of pro-inflammatory cytokines in LPS stimulation of 
PBMC. Based on these results, ginseng polysaccharides and ginsenosides are 
immunomodulatory, inducing a Th1 transcriptional profile. Our results may assist the 
development of optimized ginseng preparations with targeted immunomodulatory activity.  
 
 
Keywords 
Ginseng; Panax quinquefolius; Human; Ginsenoside; Polysaccharide; Peripheral Blood 
Mononuclear Cells; Immunomodulation; Microarray; Cytokines  
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1 Introduction 
1.1 Human Immune System  
The human immune system is a vital part of human life as it protects the body against 
harmful pathogens and internal damage. To do this, the immune system recognizes 
pathogens, eliminates them and whenever possible generates immunological memory. 
The immune system is specific to recognize pathogens and pathogen-infected cells. 
However, the ability to discriminate self non-self can be broken down, resulting in 
autoimmune diseases such as multiple sclerosis.  
The cells of the immune system are all derived from a pluripotent hematopoietic stem cell 
in bone marrow. Common lymphoid progenitor cells give rise to B cells, T cells and 
natural killer cells (NK), while common myeloid progenitor cells are the source of 
neutrophils, eosinophils, basophils, mast cells and monocytes 1. All these cell types play 
an important role in various immune responses, ensuring the optimal function of the 
immune system.  
Immune responses can be divided into two broad classifications, innate and adaptive. The 
innate immune responses are the first line of defense against an invading pathogen as 
they begin immediately after the pathogen enters the body. The innate immune responses 
include: the anatomical barriers that aim to prevent a pathogen from entering the body, 
the recognition of pathogens by Pattern Recognition Receptors (PRR) expressed in 
macrophages, neutrophils and DC and activation of the complement system, that all work 
together to eliminate the pathogen. Finally the innate immune response helps control the 
spread of pathogens. The ability of the innate immune system to respond immediately to 
pathogen invasion is accomplished by sensing what is considered a pathogen through 
detecting pathogen associated molecular patterns (PAMPs) 2.  
The adaptive immune system on the other hand is characterized by its ability to recognize 
pathogens in a specific manner and the ability to generate immunological memory. The 
main cell types of the adaptive immune system are B and T cells that have clonotypic 
receptors for billions of different antigens present in pathogens. These single specificity 
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receptors allow for the differentiation between pathogens and the specific recognition of 
pathogens. However, in order for a pathogen to be recognized by a B or T cell it must be 
phagocytosed and processed by an antigen-presenting cell (APC). Once a T cell has been 
presented with its appropriate antigen it will differentiate into effector and memory cells. 
The effector cells will begin to aid in the removal of the pathogen while memory cells 
will remain in the body long after the infection has been cleared. Due to the coordination 
required to initiate an adaptive immune response, these responses are not as immediate as 
the innate immune response and usually take one to two days to begin. However, once 
memory cells are present in the body, the adaptive immune response can begin much 
faster if the body is reinfected with the same pathogen.  
 
1.1.1 Anatomical Barriers  
Anatomical barriers are the first line of defense against invading pathogens. These 
barriers are composed of an epithelial cell layer that lines the surfaces of the body that are 
exposed to the outside. The external epithelial layer, such as skin, provides an incredible 
challenge for invading microbes containing commensal microflora to prevent the 
colonization of skin by bacteria. It is only when the epithelial layer is damaged that 
pathogens can enter the body. As a result, the majority of invading pathogens will enter 
through the internal epithelial layers in the lung or gut. These epithelial layers use 
defense mechanisms such as mucus and antimicrobial peptide secretions, pH changes and 
the presence of commensal microbiota 2.  
1.2 Innate Immunity  
Once a pathogen passes the anatomical barriers, the innate immune system is responsible 
for clearance of the pathogen. This is, in part, accomplished by the presence of preformed 
soluble anti-microbial molecules and enzymes in the blood and bodily fluid, which 
recognize common features of many pathogens such as defensins, cathelicidins and 
lysozyme 3. The complement system, a complex system of plasma proteins that target 
bacteria and viruses for lysis or phagocytosis by macrophages and other cells, is also an 
important innate immune response 4. These soluble molecules work in conjunction with 
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the macrophages, neutrophils and DC of the immune system to contain and eliminate the 
pathogen.  
If bacteria enter the body, phagocytic cells that patrol tissue for incoming pathogens will 
recognize them. Macrophages are one of the phagocytic cell types present in all tissues. 
Macrophages mature from monocytes when they exit the blood and enter the tissue 
through a process known as extravasation. Neutrophils are short-lived cells that are 
commonly found in the blood and not the tissue. Neutrophils are recruited to a tissue 
infected by a pathogen and clear the pathogen mainly by phagocytosis 5, 6.  
Alternatively, the clearance of viral infections can also use different cell types and 
mechanisms. Viral infections induce the production of the anti-viral cytokines interferon-
α (IFN-α) and IFN-β. Plasmacytoid dendritic cells have been shown to be particularly 
important for producing large amounts of interferon to aid in the antiviral response 2. 
IFN-α and IFN-β are both ligands to a common interferon receptor which, upon 
activation, induces many antiviral mechanisms including the production of proteins that 
interfere with viral replication, increased expression of co-stimulatory molecules on 
macrophages and DCs and the activation of NK cells 7.  
Innate immune responses do not provide long-term immunological memory. This is only 
accomplished by the initiation of an adaptive immune response.  
 
1.2.1 Pro-inflammatory Immune Response 
Inflammation is a very important component to pathogen clearance and plays a vital role 
in many physiological processes from repair mechanisms to facilitating of the initiation 
of an adaptive immune response. The three major roles of inflammation are to recruit 
effector cells to the site of infection, induce local blood clotting and promote pathogen 
clearance 2. The inflammatory response typically begins minutes after the initial pathogen 
is detected and can last for many days.  
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In order to initiate the pro-inflammatory response, activated macrophages secrete 
molecules such as prostaglandins, leukotrienes and platelet-activating factor. These 
molecules begin the vasodilation processes. Pathogen entry and detection also activates 
the kinin system. The kinin system is an enzymatic cascade ultimately resulting in the 
production of bradykinin to increase vascular permeability 8. Activated macrophages 
secrete tumor necrosis factor α (TNF-α) and interleukin 1β (IL-1β) which vasodilates 
surrounding blood vessels, reducing the speed of blood flow and increasing the 
expression of adhesion molecules such as P-selectin, LFA-1, V-CAM-1 and ICAM-1 9. 
Vasodilation of the surrounding blood vessels results in increased blood flow to the 
infected area and increased chance for neutrophils and NK cells to bind to the adhesion 
molecules and extravate into the tissue. TNF-α increases vascular permeability to allow 
more fluid to flow out of the blood vessels and into the tissue, bringing with it plasma 
proteins such as those in the complement cascade 2. Finally, clotting occurs in the small 
blood vessels around the site of infection to prevent the spread of the pathogen. Clotting 
of the surrounding blood vessels occurs through activation of the coagulation cascade 10.  
Another important feature to the inflammatory response is the use of chemoattractant 
cytokines known as chemokines. These small proteins direct the movement of cells 
toward the source of chemokine through changes in the cytoskeleton and adhesiveness of 
the cell. The major role of chemotaxis in the inflammatory response is the movement of 
cells out of the blood and into the site of infection. For example CCL2 attracts most 
monocytes to the site of infection and induces them to become tissue macrophages 2. This 
is similar to the role of CXCL8 that induces neutrophils to leave the blood and enter the 
site of infection 2. Not only do chemokines direct the movement of important 
inflammatory cells to the site of infection, they also promote extravasation. Chemokines 
alter the leukocyte integrins to facilitate stable binding with endothelial adhesion 
molecules such as P-selectin, LFA-1, V-CAM-1 and ICAM-1, allowing the macrophages, 
neutrophils and other cells to enter the site of infection 2. There are over 50 known 
chemokines, some of which target immune cells 2. Cytokines and chemokines work 
together to recruit immune cells to the site of infection.  
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Another way of activating pro-inflammatory responses is through the complement 
system. This plasma system is composed of more than 30 proteins that are produced by 
the liver in the absence of infection and circulate in the blood in their inactive form 2. 
These inactive proteases become active upon enzymatic cleavage typically by another 
complement protein. The interaction of the 30 complement proteins form the three major 
arms of complement activation, the classical pathway that requires the binding of 
complement component 1 (C1) to the pathogen surface or to an antibody already bound 
to the pathogen surface, the alternative pathway that can be activated by C3 activation 
and the lectin pathway that uses mannose or ficolin-binding proteins to recognize 
carbohydrate structures on the surface of pathogens 2. The lectin pathway, similar to 
macrophages and neutrophils use proteins that function as PRR to recognize PAMP. The 
three pathways converge on the key activation step of the complement system, C3 
cleavage into C3a and C3b by C3 convertase. C3b is the main effector molecule of the 
system and when it is bound covalently to the surface of the pathogen it acts as an 
opsonin, activating complement phagocytes to engulf the pathogen 2. C3b can also bind 
to the C3 convertase on lectin and antibody mediated complement cells to form C5 
convertase. C5 convertase forms C5a and C5b, C5b activates the formation of a 
membrane-attack complex leading to lysis of the pathogen 2. The byproducts C3a and 
C5a act on endothelial cells to induce inflammation by constriction of smooth muscle, 
increasing vascular permeability and inducing the synthesis of adhesion molecules 2. C3a 
and C5a also activate mast cells in mucosal epithelial layers to release TNF-α that also 
causes similar pro-inflammatory effects 2. The complement system is another way that 
the pro-inflammatory system can be activated and perpetuated.  
Pro-inflammatory immune responses, regardless of how they were initiated, must also be 
controlled. One of the mechanisms is through the use of anti-inflammatory cytokines 
such as IL-10 and transforming growth factor β (TGF-β). IL-10 reduces the intensity of 
pro-inflammatory immune responses by reducing T cell activation, IL-2 production, 
expression of major histocompatibility complex (MHC) and co-stimulatory molecules 2. 
TGF-β participates in decreasing pro-inflammatory responses by targeting T cells, 
blocking their cytokine production and killing mechanisms 2. These cytokines are 
characteristic of many regulatory cell subsets such as regulatory T cells (Tregs). These 
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cells are important for attenuation of the pro-inflammatory response 11. However, many 
other cell types can secrete IL-10 including Th1, Th2, Th17 and B cells 2.  
 
1.2.2 Lipopolysaccharide Recognition 
Lipopolysaccharide (LPS) is a structural component of the outer cell wall of gram-
negative bacteria. It is an endotoxin and produces strong immune responses in mammals. 
Each LPS molecule has three separate domains, namely the O-antigen, the core and the 
lipid A domains 3. The O-antigen is a repetitive glycan polymer that makes up the 
outermost portion of LPS. The longer the O-antigen polymer chains are, the more 
difficult it is to penetrate the bacteria 12. The core domain can contain many compounds 
including phosphates and amino acids. However it will always contain an oligosaccharide 
that is used to bind the lipid A domain 12. Lipid A is a phosphorylated glucosamine 
disaccharide with multiple hydrophobic fatty acids attached and is responsible for the 
toxicity of LPS 13. The fatty acids attached to lipid A anchor LPS into the bacterial 
membrane 14.   
The LPS receptor is found on the surface of DC and macrophages and is composed of 3 
subunits, cluster of differentiation 14 (CD14), Toll like receptor 4 (TLR-4) and MD-2. 
These three clusters work together to recognize and signal the presence of LPS, CD14 is 
a GPI-anchored protein and requires TLR-4 to signal, while TLR-4 requires the accessory 
protein MD-2 for correct trafficking to the cell surface as well as for LPS recognition 3. 
The lipid domains of LPS bind to the hydrophobic cup in MD-2 of one TLR-4 MD-2 
complex 15. The binding of LPS to one complex recruits a second TLR-4 and MD-2 
complex that further binds the LPS lipid and carbohydrate domains resulting in a TLR-4 
dimerization and activation of downstream signaling cascades 16. Some LPS can break 
free from the cell wall and be picked up by an LPS binding protein. In this case, LPS is 
transferred from the LPS-binding protein to CD14 on the surface of monocytes and 
macrophages 17. LPS binding to CD14 still results in the dimerization of TLR-4 and MD-
2 and the activation of the same downstream signaling cascades.  
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TLR-4 dimerization brings together the cytoplasmic toll/interleukin-1 receptor (TIR) 
domains of TLR-4 to interact with TIR domains of certain adaptor molecules. Based on 
the TLR-4 ligand, there are two possible signaling cascades used, the myeloid 
differentiation factor 88 (MyD88)-dependent pathway is used for recognition of bacterial 
pathogens, while the MyD88-independent pathway is used for recognition of viral 
pathogens. In the MyD88-dependent pathway, TLR-4 uses the adaptor molecules MyD88 
and MyD88 adaptor-like (MAL), which recruit IL-1 receptor activated kinase (IRAK1) 
and IRAK4 18. The activation of IRAK4 is required for the function of the MyD88- 
dependent pathway and IRAK4 inactivation leads to a rare immunodeficiency resulting in 
recurrent bacterial infections 18. Ultimately, the MyD88 dependent cascade results in the 
activation and translocation of nuclear factor kappa-light-chain-enhancer of activated B 
cells (NF-κB) into the nucleus to induce the transcription of pro-inflammatory cytokine 
genes such as IL-1β, IL-6 and TNF-α 19. Alternatively, in the MyD88-independent 
pathway, TLR-4 uses the adaptor molecules TIR domain-containing adaptor-inducing 
IFN-β (TRIF) and TRIF-related adaptor molecule (TRAM). These adaptor molecules 
ultimately induce the downstream phosphorylation of the interferon regulatory 
transcription factor 3 (IRF3), inducing the expression of IFN-β 5, 20, 21. 
 
1.3 Adaptive Immunity 
While there is significant cross talk between the innate and adaptive immune systems, the 
adaptive immune system is still very distinct. The main function of the adaptive immune 
system is to recognize pathogens in a specific manner and generate immunological 
memory to those pathogens. The cells responsible for these functions are the B and T 
cells. B and T cells have clonotypic receptors to billions of different antigens 22. When 
naïve B and T cells are presented with an antigen that they can bind, they will undergo 
proliferation and differentiate into effector cells and memory cells.  
The major function of B cells is to produce antibodies and contribute to immunological 
memory. B cells are formed in the bone marrow and migrate to the spleen to mature. 
During development a B cell receptor (BCR), membrane bound immunoglobulin, is 
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formed on all B cells, each composed of two heavy chains and two light chains 2. Both 
heavy and light chains have a variable region, used to recognize the antigen, and a 
constant region that determines the function of the antibody. Genetic recombination of 
the variable (V), diversity (D) and joining (J) gene segments known as VDJ for the heavy 
chain and VJ recombination for the light chain variable regions are used to create a vast 
number of BCRs each with a unique specificity 23. There are also five different constant 
regions encoded on separate heavy chain C-region genes. IgM, IgD, IgG, IgE and IgA 
differ in the number of disulfide bonds, the presence or absence of a hinge region, the 
number and location of sugar groups, the number of domains in the constant region as 
well as the function of the antibody 2. Once a B cell comes into contact with its specific 
antigen, it will then differentiate into plasma cells that secrete large amounts of soluble 
BCR known as antibodies, with the exact same specificity as the BCR 2. Activated B 
cells will also form memory B cells, which are long lived cells that are able to respond 
more quickly if the pathogen is reencountered at a later time.  
T cells also recognize antigens in a specific way and create immunological memory. 
However, T cells do so in a very different way from B cells. T cell antigen recognition is 
controlled by transmembrane glycoproteins known as MHC molecules. These molecules 
contain a cleft on their surface to which a peptide antigen can be bound and recognized 
by a T cell. TCRs recognize features of the MHC molecule and the peptide antigen, 
known as MHC restriction 2. Like B cells, T cells are also formed in the bone marrow but 
mature in the thymus. During development, they use similar gene rearrangement 
processes to develop a vast repertoire of T cell receptors (TCRs). Similar to the BCR, the 
TCR also has a heavy and light chain, TCRα and TCRβ respectively, each with a variable 
region used to specifically recognize pathogens 24. TCRα undergoes Vα and Jα gene 
recombination while the TCRβ undergoes Vβ Dβ Jβ gene recombination 24. Subsequent to 
TCR formation, T cells undergo positive and negative selection in the thymus to remove 
auto-reactive T cells and subsequently differentiate them into CD4+ or CD8+ T cells.  The 
TCR is made up of two polypeptide chains, the majority of which are α and β chains 25. 
These heterdimers are connected by a disulfide bond and recognize the majority of T cell 
antigens 25. There are also γ and δ polypeptide chains that appear in a substantially 
smaller number of T cells 25. The γ:δ heterodimers recognize their antigens directly and 
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does not require them to be presented in MHC molecules 25. Because of this γδ T cells are 
considered to be innate-like immune cells 2.  
Naïve CD4+ and CD8+ T cells circulate through the peripheral lymphoid tissue in search 
of their antigens. An adaptive immune response begins when a DC or any other type of 
professional antigen-presenting cell (APC) presents an antigenic peptide to a T cell with a 
TCR specific to that peptide. In CD8+ cells that peptide would be presented on a MHC 
class I molecule, whereas CD4+ T cells recognize longer peptides presented on MHC 
class II molecules.  The APC must also present T cells with appropriate co-stimulatory 
signals such as CD80/CD86, to prevent cells from becoming unresponsive or anergic 2. T 
cells also have mechanisms to prevent the recognition of self-peptides and subsequent 
death of self cells. For example, in antigen presentation of a pathogen, B7 binds CD28. 
However, when self peptides are presented, there is commonly a lack of CD28 on the cell 
surface. Therefore, the absence of CD28 signals that the presented peptide is a self 
peptide 26. The activation of the TCR ultimately results in the activation of NF-AT, NF-
κB and MAPK. The activation of these signalling molecules will eventually result in the 
transcription of the IL-2 gene and ultimately IL-2 production leading to T cell 
proliferation.  
Activated CD4+ and CD8+ T cells begin dividing into approximately 1000 clonal effector 
cells in the next three to five days 2. Effector CD8+ T cells are cytotoxic T cells that will 
go on to kill virally infected cells. Likewise, CD4+ effector cells are T helper (Th) cells 
that go on to provide additional signals to other cells in the immune system 27. Some 
effector T cells will migrate to the site of infection and others will stay in the lymphoid 
tissue to activate B cells 2. A subset of these antigen-experienced cells will persist as 
memory cells. Like memory B cells, their function is to decrease the time required to 
initiate an adaptive immune response when the same antigen is encountered.  
The adaptive immune system is concerned with specific recognition of pathogens and 
creating immunological memory for these pathogens. However, the adaptive immune 
system could not function properly without the APCs and more specifically the DCs of 
the innate immune system.  
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1.3.1 Th1, Th2 and Th17 T cell responses 
Upon antigen recognition, T cells differentiate into effector cells. CD8+ T cells become 
cytotoxic T cells that kill infected cells, while CD4+ T cells can differentiate down 
distinct pathways that generate subsets with different effector functions. There are 
currently four different effector subsets that are well defined: T helper 1 (Th1) cells, Th2 
cells, Th17 cells and T follicular helper (TFH) cells. The identification of these subsets is 
based on the profile of cytokine production resulting from activation.  
Naïve T cells differentiate into the different effector subsets (e.g. Th1, Th2, Th17 and TFH) 
depending on the cytokine microenvironment. Th1 cells are the result of differentiation in 
the presence of IL-12 and IFN-γ 28, 29. This is because IFN-γ and IL-12 activate the janus 
tyrosine kinase (JAK) and signal-transducing activators of transcription (STAT) 
intracellular pathways to alter gene transcription. Initially, IFN-γ is produced by activated 
NK cells as the IFN-γ gene in CD4+ T cells is turned off 2. In the presence of IFN-γ and 
IL-12, STAT1 is activated and induces the expression of the transcription factor T-bet, 
which switches on the IFN-γ gene and the IL-12 receptor 30. Once this occurs cells are 
committed to the Th1 pathway. IL-12 can then be induced by STAT4 to promote the 
differentiation and expansion of Th1 committed cells 2. Th1 effector cells will produce a 
large amount of IFN-γ when they encounter antigen, which further signals the 
differentiation of more Th1 cells. 
The effector function of Th1 cells is unique from other linages. Th1 cells are involved 
primarily with the killing of intracellular bacteria in macrophages. Under normal 
conditions, macrophages phagocytose and degrade bacteria in the phagolysosome. 
However, some bacteria evolve mechanisms to persist intracellularly in macrophages and 
evade the macrophage killing mechanisms. In this situation, Th1 cells interact with such 
macrophages to activate their anti-microbial activity to kill the resident bacteria 2. Th1 
effector T cells also play an important role in the killing of virus infected cells by 
orchestrating the differentiation of CD8+ T cells into cytotoxic cells 27. Th1 cells increase 
the activation of naïve CD8+ T cells by secreting IL-2 to increase the expression of the 
co-stimulatory signals, B7 and 4-1BBL on dendritic cells 2. B7 and 4-1BBL provide 
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additional co-stimulatory signals to CD8+ T cells to aid in differentiation into cytotoxic 
cells 2.  
The differentiation of a naïve CD4+ T cell down the Th2 pathway is dependent on the 
presence of IL-4 during maturation. This is because IL-4 activates the STAT6 receptor on 
T cells promoting the expression of GATA3 31. Th2 T cells are functionally distinct from 
Th1 in that Th2 cells control parasite infections by promoting responses of eosinophils, 
mast cells and IgE antibodies. Specifically, IL-4, IL-5, IL-9 and IL-13 are secreted from 
T cells and required to switch B cells to produce IgE antibodies 32.  
Finally, Th17 cells arise in the presence of IL-6 and TGF-β and the absence of IL-4 and 
IFN-γ during maturation 33. Th17 cell development involves an initial production of IL-21 
to activate STAT3, a transcription factor required for Th17 cell production 30. RORγT is 
the transcription factor expressed by differentiated Th17 cells and enables them to 
produce IL-17 in the absence of IFN-γ and IL-4 34. Th17 T cells protect against infection 
by extracellular bacteria and fungi through stimulating the neutrophil response that helps 
clear pathogens.  
Another function of CD4+ T cells is to provide help to B cells to produce antibodies. This 
is because effector T cells secrete the required cytokines to induce isotype switching 
resulting in different effector functions of antibodies. For example, of the characteristic 
Th2 cytokines IL-4 and IL-5, IL-4 increases the class switching of antibodies to IgG4 and 
IgE, while IL-5 increases class switching to IgA 35. While IFN-γ and IL-2 the 
characteristic Th1 cytokines increase the class switching of antibodies to IgG2a and IgG3 
35
.  
 
1.3.2 Staphylococcus aureus Enterotoxin E Recognition 
S. aureus is a gram-positive bacteria that can live as a commensal in the nose and skin. It 
causes a wide variety of skin and soft tissue infections as well as more invasive diseases 
leading to bacteremia and sepsis 36. S. aureus strains have been shown to produce up to 
20 seriologically distinct superantigens. Superantigens are small, secreted pyrogenic 
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exotoxins, with a molecular weight between 20 – 28 kDa 37. Superantigens have two 
domains, the A domain contains a C-terminal β-motif and a central α-helix region, while 
the B domain contains the N-terminal oligosaccharide binding domain 38.  
Superantigens have a distinct method of binding to both the MHC complex and the TCR 
in order to activate a large number of T cells. Normal T cell antigens bind MHC 
molecules in the peptide-binding groove. Alternatively, superantigens do not bind this 
groove and instead bind to the outside surface of the alpha or beta chains of some MHC 
class II molecules 36. In this way, superantigens can activate up to 20% of all T cells, 
which is substantially more than a normal T cell antigen 39. Due to the non-specific 
activation of T cells induced by superantigen stimulation, the resulting response is not 
specific to the pathogen. Instead, the broad activation of T cells results in large scale 
production of IL-2, an inducer of T cell proliferation, and ultimately suppresses the 
adaptive immune response as a consequence of activation-induced cell death resulting in 
a cytokine storm and systemic toxicity 40.  
S. aureus can also cause a number of skin and systemic infections including impetigo, 
staphylococcal scalded skin syndrome, toxic shock syndrome (TSS), osteomyelitis and 
endocarditis 41. The wide array of diseases induced by this single pathogen is in part due 
to the fact that its virulence factors have a number of different targets including 
neutrophil chemotaxis, inhibition of complement mediated opsonization, disruption of 
epithelial layers and inactivation of antimicrobial peptides 42. S. aureus also has a number 
of virulent superantigens that cause diseases. For example, TSS can be a life-threatening 
disease that is induced by the toxic shock syndrome toxin 1 (TSST-1) of S. aureus 42. 
TSST-1 also causes a similar but much less sever disease in neonates known as neonatal 
toxic shock syndrome-like exanthematous disease 42. The superantigens of S. aureus can 
also be used as a tool to activate and study T cell activation in the laboratory. Due to the 
specific nature of T cell activation through conventional means, it is very difficult to 
purify an antigen specific population of T cells. Therefore, superantigen stimulation can 
be used as a model of T cell activation. 
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1.4 Introduction to North American Ginseng  
1.4.1 The History of Ginseng  
Generations of people have used natural products in medicine, cosmetics, dyes and 
beverages to promote health and longevity. Among these, ginseng is considered the most 
prized plant in Asia and is growing in popularity worldwide 43. The first known 
documentation of ginseng use was in the commentary book, “Shennong Bencao Jing 
(Shennong’s Herbal)” by Tao Hongjing and written in the Liang Dynasty, 502-557 A.D. 
44
. It was based on the findings of Chinese Emporor Yan, considered to be the father of 
natural medicine for his role in the discovery of many medicinal plants 45.  
The discovery of ginseng in North America did not occur until 1709 when Father Jartoux, 
a Jesuit missionary in China, wrote a letter describing the ginseng root and its properties 
to Father Lafitau in St. Louise, Canada, near Montreal. In 1714 Lafitau recognized the 
description of ginseng as a plant that he often saw in the forest. At that time North 
American ginseng grew only in southern Canada and the eastern United States 43. Once 
farmers knew of the proposed health benefits of ginseng based on traditional Chinese 
medicine, an intense effort was made to cultivate the prize crop. It was not until 1897 
when George Stanton discovered the importance of growing ginseng in the shade, that 
this effort succeeded and cultivation became a reality 46.  
North American and Asian ginseng are part of the Panax genus along with 10 other 
ginseng species 47. There are also 12 other ginseng-like species classified into other 
genuses. However, the Panax genus, including Asian ginseng (P. ginseng) and North 
American ginseng (P. quinquefolius) are considered true ginseng as they produce 
ginsenosides, unique to the ginseng plant. Due to the unique growing conditions ginseng 
requires and the wide spread over-harvesting of ginseng in the early 1900’s North 
American ginseng is currently only grown in southwestern Ontario and the state of 
Wisconsin. In order to help prevent the further over harvesting of North American 
ginseng, in 1973 P. quinquefolius was listed in Appendix II of the Convention on 
International Trade in Endangered Species of Wild Fauna and Flora (CITES). 
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Accordingly, the federal government must approve all exports of ginseng, deeming that 
export will not be detrimental to the survival of the species in the wild 48. 
In recent years there has been an increased number of people using ginseng in North 
America. Due to the readily available supply of North American ginseng and the high 
costs of Asian and other types of ginseng, North Americans have been consuming North 
American ginseng more than any other type. However, there is a major lack of scientific 
evidence to validate the claims traditionally attributed to Asian ginseng for North 
American ginseng.  
 
1.4.2 Ginseng Plant  
Ginseng is a perennial plant that is often difficult to grow as it is highly affected by soil 
moisture, temperature changes and soil composition 49. However, even under ideal 
conditions, ginseng is still a very slow growing plant and takes 4-6 years before it can be 
harvested. When fully mature, ginseng plants produce edible red berries and large leaves 
but it is its extensive underground root systems that is typically harvested 50.    
The harvest of ginseng roots is labor intensive and kills the entire plant. Once ginseng is 
harvested, it has to undergo significant processing for its commercial use including 
heating and drying. The type of ginseng produced is dependent on the age of the ginseng 
plant at the time of harvest and the type of post-harvest processing it undergoes 51. For 
example, if the roots are harvested less than 4 years after they were planted then they are 
called fresh ginseng and do not require processing. White ginseng roots are harvested 
between 4 - 6 years after planting and they are peeled and dried. Lastly, red ginseng is 
harvested 6 years after planting and it is steamed at 100 °C and dried 43. The various 
methods of processing ginseng roots have been shown to change the content of the root 
as well as it’s the composition of ginsenosides 52, 53.  
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1.5 Ginseng Components 
While the root of the ginseng plant is the part of the plant most commonly used, all of the 
compounds present in the root are present throughout the plant in different concentrations 
including the leaves, stems and berries. The five compounds of interest with respect to 
ginseng are the peptides, fatty acids, polyacetylenes, ginsenosides and polysaccharides. 
The peptides and fatty acids of ginseng have not been isolated for study as 
immunomodulatory compounds. However, extensive research using isolated 
polyacetylenes, ginsenosides and polysaccharides has been carried out each yielding very 
different results.  
 
1.5.1 Polyacetylene Compounds  
Polyacetylenes are long organic polymer chains with a (C2H2)n repeating structure that 
can be found in many plant species including carrots (Daucus carota L.) 54. There are 
seven major polyactylenes that are common across many species of ginseng including 
panaxynol, ginsenoyne –A, panaxydol, 10-methoxy heptadeca-1-ene-4, 6-dyne-3, 9-diol, 
panaxytriol, panaxyne and ginsenoyne – C. The ratio of these compounds changes based 
on the growth conditions of the ginseng as well as its post-harvest processing. However, 
many of these compounds have been shown to play a key role in ginsengs anti-tumor and 
anti-cancer properties. For example, in a mouse xenograft model panaxydol was shown to 
decrease the toxic side effects associated with standard cancer treatment such as weight 
loss, peripheral neuropathy and hematotoxicity 47. Furthermore, panaxydol has also been 
shown to preferentially induce apoptosis in human cancer cells through a caspase-
dependent and mitochondrial-mediated response 55. Finally, panaxytriol has been shown 
to cause significant cytotoxicity and inhibit DNA synthesis in multiple tumor cell lines 56.  
 
1.5.2 Ginsenosides 
Ginsenosides have been claimed to be the active ingredients of ginseng for many years. 
Ginsenosides are low molecular weight steroidal saponins unique to the Panax genus. 
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The two most common groups of ginsenosides are the protopanaxadiol and 
protopanaxatriol ginsenosides. These groups differ in their 4-trans ring steroidal 
backbone 57. In order to create unique ginsenosides from the protopanaxadiol backbone, 
sugar moieties are attached to the β-OH at carbon 3 and/or carbon 20. Likewise, unique 
ginsenosides are created by the addition of sugar groups to the α-OH at carbon 6 and/or 
the β-OH at carbon 20 of the protopanaxatriol backbone 7. The differential addition of 
sugar side chains has resulted in the presence of over 100 unique ginsenosides. These 
sugar groups are deglycosylated by intestinal bacteria such as Bacteroides sp. 58, 
Bifidobacterium sp. 59, Fusobacterium sp. 60, Lactobacillus delbrueckii 61, and 
Leuconostoc paramesenterioides 61 into their biologically active forms upon ingestion.  
The types of ginsenosides present in extracts are also very important to the biological 
function of that extract, as different ginsenosides appear to have different effects on the 
body. There are many factors that affect the content of ginsenosides present in ginseng 
roots including age, root dry weight, soil fertility, light, population size and location 62.  
The majority of ginseng research has focused on ginsenosides as the active components. 
A large amount of this research has been carried out using specific ginsenosides to 
determine their immunomodulatory function. For example, ginsenosides have repeatedly 
been shown to have anti-tumor properties 63-65. Ginsenosides also have strong effects on 
diabetes, for example, Rb2 inhibits gluconeogenesis through the AMPK pathway 66. Rb3 
and other ginsenosides have also been shown to have mood enhancing effects 67, 68.  
 
1.5.3 Polysaccharides  
The saccharide component of ginseng includes oligosaccharides, pectic polysaccharides 
and starches 69. Preliminary data indicates that some of these saccharides originate from 
the cell wall of ginseng plant cells. However, not all polysaccharides present in the 
extracts were detected using their methods 70. The remaining unidentified 
polysaccharides may or may not be part of the cell wall of ginseng plant cells or other 
organelles in the ginseng plant. Many saccharides have been identified in both Chinese 
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and North American ginseng extracts to be important in the immunomodulatory response 
of ginseng including ginsan 71, panaxans, arabinogalactans 72, rhamnogalacturonan II 73, 
galactose, arabinose, rhamnose, and glucose, as well as monosaccharides fucose and 
mannose 74. 
While significantly less research has been done on polysaccharides than ginsenosides, 
polysaccharides are emerging as the new immunomodulatory compounds of ginseng. For 
example, ginseng polysaccharides have been key in advancing the use of ginseng as an 
adjuvant. This is because complex polysaccharide extracts have been shown to induce 
more IgG production compared to control 75. Ginseng has also been shown to have strong 
bacteriocidal activity against many bacteria including S. aureus 76. Finally, 
polysaccharides have also been shown to induce the formation of regulatory T cells 
through the activation of FoxP3 resulting in less severe experimental autoimmune 
encephalomyelitis 77.  
 
1.5.4 Composition of North American Ginseng Extracts 
As previously discussed, the majority of ginseng research has been done using single 
purified compounds of ginseng. However, this does not represent how ginseng is 
currently being used. In order to mimic the current uses of ginseng worldwide, we used 
an aqueous, polysaccharide and ethanol extract in our studies. These extracts most closely 
mirror the use of ginseng in tea and soup, candy and alcoholic beverages such as wine 
and whiskey respectively. Due to the chemical properties inherent in the solvents 
required to make the three extracts, the composition of each extract is vastly different. 
The ethanol extract is composed of a complex mixture of ginsenosides 78. While the 
aqueous extract contains the same complex mixture of ginsenosides, it also contains the 
polysaccharides of the ginseng root as well 78. Finally, the polysaccharide extract is 
prepared by precipitating out the polysaccharides from the aqueous extract, therefore it is 
only composed only of the polysaccharides in the aqueous extract 78.  
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1.5.5 Composition of COLD-FX® 
COLD-FX® is a major reason why the use of North American ginseng has increased in 
recent years as it is composed of over 80% poly-furanosyl-pyranosyl-saccharides, 
isolated from a North American ginseng aqueous extract 79. Therefore, COLD-FX® is 
used as a control for my work as it is a commercially prepared product made by Afexa 
Life Science Inc. This polysaccharide family is isolated from the roots of North American 
ginseng using an aqueous extract and further precipitation by ethanol, similar to the 
preparation of our polysaccharide ginseng extract.  
The major claim of COLD-FX® is that it can decrease the frequency and severity of cold 
and flu symptoms. This claim was substantiated in a clinical trial of immune competent 
elderly people, where taking COLD-FX® for four months reduced the relative risk of 
respiratory symptoms of cold and flu by 48-55% 80, 81. These results may be in part due to 
the COLD-FX® induced maturation of monocyte derived dendritic cells 82, increased 
presence of memory T cells and the induction of prototypical Th1 cytokines including IL-
12 and IFN-γ which have been reported by other groups 79.  
 
1.6 Experimental Rational, Hypothesis and Specific Aims 
Ginseng has been thought to regulate the immune system since its discovery thousands of 
years ago. However, the majority of ginseng research has used Asian ginseng and 
focused on specific compounds including single ginsenosides or polyacetylenes. These 
compounds have been used to determine their effects in narrow experimental conditions, 
disregarding their effects on the immune system as a whole. Furthermore, the use of 
individual purified compounds is not representative of how ginseng is currently being 
used. Ginseng is currently being used in the form of ginseng extracts. These complex 
solutions contain many different compounds isolated from ginseng. By using North 
American ginseng extracts to stimulate PBMC the results represent more accurately 
represent the effect of ginseng, in the way it is currently being used, on the human 
immune system. This is required to fully understand the effects of one of the most widely 
used natural medicine products in the world.  
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While the search for the active immunomodulatory compounds of ginseng proceeds, it is 
important to use a biologically relevant system to determine the immunomodulatory 
effects. For this research PBMC were used as they closely reflect systemic effects due to 
blood bioavailability. The majority of previous ginseng research has been done using 
leukemia cell lines that represent only single cell types of the immune system50, 57, 78. 
These cells are often much larger than average immune cells and have differential 
expression of receptors as compared to healthy PBMC. By using PBMC for our research 
we negate the altered cell size and changes in receptor expression often found in these 
cells.  
Our lab became interested in defining the immune effects of North American ginseng. To 
do this we used three extracts, the aqueous, polysaccharide and ethanol North American 
ginseng extracts, in order to mimic how ginseng is currently consumed. Preliminary data 
confirmed the induction of the pro-inflammatory cytokines IL-6, IL-1β and TNF-α by 
North American ginseng aqueous and polysaccharide extracts as well as COLD-FX® in 
human PBMC 83. Our lab also determined that the compounds responsible for this 
activation were water-soluble compounds found in the aqueous and polysaccharide North 
American ginseng extracts with a molecular weight greater than 77,000 Da. These 
compounds induced the greatest amount of phosphorylation of the AKT, NF-κB and 
ERK-1/2 signaling molecules in PBMC when compared to compounds of molecular 
weight less than 77,000 Da and the aqueous or polysaccharide extracts 83. This lead to the 
idea that ginseng extracts are immunomodulatory, however further work was required to 
determine the exact responses which were affected and what the active compounds were. 
It also remained unclear whether or not there is any antagonism between the different 
compounds in the three extracts tested.  
 
1.6.1 Hypothesis  
Our preliminary data suggest that ginseng has an immunomodulatory effect on the innate 
and adaptive immune responses of PBMC. Therefore, I am proposing that the 
modulatory effects of ginseng extracts on human innate and adaptive immune 
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responses are mediated by water-soluble compounds with a molecular weight 
greater than 77 kDa found in the aqueous and polysaccharide ginseng extracts. In 
order to address this hypothesis I will address the innate and adaptive immune responses 
in the presence of ginseng, by determining the effects of ginseng treatment on pro- and 
anti-inflammatory cytokine production in response to different stimuli. I will then use 
cytokine production as a read out for the effect of ginseng on representative innate and 
adaptive immune responses, induced by LPS or SEE respectively. I will then define the 
transcriptional profile induced by the aqueous extract through the use of microarray 
analysis, followed by heat mapping and ingenuity pathway analysis. In addition, I will 
fractionate the aqueous and polysaccharide extracts to isolate the fractions containing the 
active immunomodulatory compounds of ginseng. I will do this by using differential 
fractionation with ultra centrifugal filter units and using cytokine production as a read out 
for immunomodulatory capacity. Finally, I will characterize the antagonistic effects of 
ginsenosides on the effect of the aqueous or polysaccharide ginseng extracts.  
 
1.6.2 Specific Aim One: To establish the effects of ginseng extracts on 
innate and adaptive immune responses of human PBMC. 
In order to understand the effects of North American ginseng extracts on PBMC, we 
began by looking at the effects of ginseng stimulation on the induction of pro- and anti-
inflammatory cytokines. We chose IL-6, IL-1β and TNF-α as pro-inflammatory cytokines 
and IL-10 as a representative anti-inflammatory cytokine. As expected from the 
literature, ginseng induced a large production of pro-inflammatory cytokines by PBMC. 
However, ginseng treatment also induced the production of a large amount of IL-10. The 
magnitude of cytokine production was not equal between the extracts, as the 
polysaccharide and aqueous extracts consistently induced the greatest cytokine 
production with minimal or no cytokine production induced by the ethanol extracts. In 
order to ensure that this effect was not specific to the ginseng produced at one single 
farm, we used three different ginseng extracts from seven different ginseng farms across 
southwestern Ontario. LPS contamination was ruled out through polymyxin B treatment. 
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Therefore, the induction of cytokines was based on properties of the compounds in the 
extracts themselves.  
To determine if the pro-inflammatory cytokines were derived from monocytes or another 
cell population, we isolated two monocyte subsets and compared the level of IL-6 
production with PBMC. CD14+CD16- and CD14+CD16+ monocytes were used as they 
have different potencies of antigen presentation on the cell surface, with CD14+CD16+ 
monocytes having a higher potency of antigen presentation than CD14+CD16- monocyte 
84
. When PBMC were treated with the aqueous or polysaccharide North American 
ginseng extracts or COLD-FX®, there was no significant difference in the IL-6 
production by either of the two monocyte populations. However, both monocyte cell 
populations produced significantly less IL-6 then PBMC treated with the aqueous or 
polysaccharide ginseng extracts. Interestingly, there was no difference in the IL-6 
production between PBMC and either of the monocyte cell populations tested when 
treating cells with COLD-FX®. Therefore, it appears that the complex mixture of 
polysaccharides present in both the aqueous and polysaccharide extracts are able to 
activate multiple cell types including B cells, T cells, NK cells, monocytes, macrophages, 
DC and basophils, while the single polysaccharide family present in COLD-FX® can only 
activate monocytes.  
To define the effects of ginseng extracts on the innate and adaptive immune responses, 
we used LPS and SEE to induce characteristic responses respectively. After co-
stimulation of PMBC with LPS and any of the three ginseng extracts it was determined 
that none of the extracts have any effect on the IL-6 response to LPS. Production of IL-6 
was used as a readout of cell activation, and this trend was observed across a variety of 
LPS and extract concentrations. Alternatively, when PBMC were co-cultured with 
various concentrations of the superantigen SEE and one of the three ginseng extracts, 
using IL-2 as a readout of T cell activation, the aqueous and polysaccharide ginseng 
extracts decreased the adaptive immune response to SEE. These results were also 
confirmed with extracts from all seven different farms of ginseng.   
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Since the induction of pro- and anti- inflammatory cytokines, as well as the suppression 
of IL-2 production in response to SEE was ubiquitous across all seven farms. Extracts 
from farm three gave the greatest extract yield and were therefore the only extracts used 
in further experiments.  
 
1.6.3 Specific Aim Two: To define the transcriptional profile induced 
by the aqueous ginseng extract. 
To determine the transcriptional profile induced by the aqueous ginseng extract on human 
PBMC, microarray analysis was performed on two independent donors. After exclusion 
of genes with less than a 2 fold change, there were 104 commonly up-regulated genes 
between the two donors and 53 commonly down-regulated genes. Interestingly, IFN-γ the 
characteristic TH1 cytokine was the top up-regulated gene, while formyl peptide receptor 
3 (FPR3) was the most down-regulated gene. When the changes in gene expression were 
mapped using heat mapping, there were obvious similarities between the gene expression 
changes of both donors after treatment with the North American ginseng aqueous extract.  
Using Ingenuity Pathways analysis (IPA) the top 20 up-regulated genes were used as the 
basis to form a network of the pathways that are most perturbed by transcriptional 
changes at those genes. This analysis led to the inferred modulation of the MAPK (ERK-
1/2), PI3K, p38 and NF-κB pathways in response to treatment of PBMC with the aqueous 
ginseng extract. This network, along with the rest of the microarray data, presents a 
profile of immunomodulation, specifically of a TH1 response by signaling through the 
MAPK (ERK-1/2), PI3K, p38 and NF-κB pathways.  
In order to confirm the up-regulation of IFN-γ, IL-12p40, IL-12p70 and IL-23 observed 
in microarray analysis, we used ELISA analysis to quantify protein. Similar to previous 
results, the aqueous ginseng extract induced significant amounts of IFN-γ, IL-12p40, IL-
12p70 and IL-23 while the ethanol ginseng extract only produced significant amounts of 
IL-12p40. However, the polysaccharide extract only induced significant levels of IFN-γ 
IL-12p40 and IL-23. Contrary to previous results COLD-FX® did not induce significant 
amounts of any of the four cytokines tested. Similarly, to confirm the result of CD14 
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down-regulation observed in microarray analysis flow cytometry was used. Both COLD-
FX® and the aqueous ginseng extract resulted in a significant decrease in surface 
expression of CD14.  
 
1.6.4 Specific Aim Three: To perform a preliminary isolation and 
characterization of the active immunomodulatory compounds of 
ginseng.  
To further investigate the active immunomodulatory compounds of ginseng, the aqueous 
and polysaccharide extracts were fractioned using differential fractionation with ultra 
centrifugal filter units. The aqueous and polysaccharide extracts were chosen as they 
induced a much greater response in cytokine production, as well as were the only extracts 
to have an effect on the SEE response. When PBMC were treated with the fractions of 
the aqueous and polysaccharide extracts, the only fraction which was able to come close 
to recapitulating the IL-6 response of the extracts themselves was the greater than 100 
kDa fraction. Furthermore, the other four fractions did not induce a similar profile of 
cytokine production; the production induced by these fractions was much less than that of 
the extracts themselves. This result was reflected in both the aqueous and polysaccharide 
extracts. Moreover, the ability of the fractions to induce the production of other cytokines 
including IL-1β and TNF-α was measured also, with similar trends as the IL-6 data 
presented.  
In order to further understand the effect of the greater than 100 kDa fraction in its 
capacity to immunomodulate, we determined the effect of the fractions compared to the 
aqueous and polysaccharide ginseng extracts on the SEE response. PBMC were co-
treated with SEE and the different ginseng fractions from the aqueous and polysaccharide 
extracts, as well as the extracts themselves. Similar to the previously observed profile, 
only the greater then 100 kDa fraction had a similar effect on the SEE response as the 
extracts.  
Ginsenosides, low molecular weight saponin molecules unique to GS, have historically 
been considered the active immunomodulatory ingredients of ginseng. However, since 
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this conflicted with our previous results, we obtained 11 purified, biologically active 
ginsenosides and two ginsenoside mixtures to test their immunomodulatory capacity. C-
Y, C-Mc and Gyp LXXV (pure) induced the pro-inflammatory cytokine IL-1β, while C-
Y, C-Mc, Gyp LXXV (pure), C-O and Gyp XVII (mixture) induced significant IL-6 
production in PBMC.  However, contrary to the effects of the ginseng extracts, all of the 
13 ginsenosides tested decreased IL-6 production in response to LPS. Alternatively, none 
of the ginsenosides tested had a biologically relevant effect on the response to SEE.  
The observation that ginsenosides down-regulate the LPS response while the aqueous and 
polysaccharide extracts had no effect on the LPS response, implied the existence of a 
possible antagonistic effect between ginsenosides and the other components of the 
extracts, in particular the polysaccharides in the ginseng extracts. To determine if this 
was the case, PBMC were co-stimulated with ginsenosides and the aqueous or 
polysaccharide extract. While none of the ginsenosides tested antagonized IL-1β induced 
by the polysaccharide ginseng extract, C-Mc1, C-K, C-Mc, C-O, C-Y, Gyp XVII (pure), 
F2, PPD, Rg3 and Rh2 antagonized the IL-1β induced by the aqueous extract.  
The antagonism of the aqueous ginseng extract prompted us to further characterize the 
effects of ginsenosides on PBMC treated with either the aqueous or polysaccharide 
extract when challenged with LPS or SEE. All of the 13 ginsenosides tested except Gyp 
LXXV (mixture), Gyp XVII (mixture) and Gyp LXXV (pure) antagonized the IL-6 
production of PBMC treated with LPS, the aqueous ginseng extract and a ginsenoside, 
when compared to PBMC treated with LPS and the aqueous ginseng extract. 
Furthermore, there was no meaningful biological difference between PBMC treated with 
LPS, the polysaccharide ginseng extract and a ginsenoside when compared to PBMC 
treated with LPS and the polysaccharide ginseng extract. Similarly, when the IL-2 
production of PBMC treated with SEE, the aqueous ginseng extract and ginsenosides was 
compared to that of PBMC treated with SEE and the aqueous ginseng extract, Gyp XVII 
(mixture), F2, Rh2 were the only ginsenosides that did not result in an increase in IL-2 
production. While, when PBMC were treated with SEE, the polysaccharide ginseng 
extract and a ginsenoside was compared with the IL-2 production of PBMC treated with 
SEE and the polysaccharide ginseng extract, only Gyp XVII (mixture) and Gyp XVII 
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(pure) resulted in an increase in IL-2 production. Based on our results it is likely that the 
antagonism of ginseng polysaccharides by ginsenosides occurs at a common step 
downstream of the binding receptor for each compound. This also has major implications 
for the use of ginseng extracts and it may be more beneficial to use single compounds of 
ginseng based on the desired outcomes. For example, ginseng polysaccharides may be 
more beneficial for increasing pro-inflammatory cytokine secretion, while ginsenosides 
decrease the immune response to LPS.  
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2 High Molecular Weight Polysaccharides are Key 
Immunomodulators in North American Ginseng Extracts: 
Characterization of the Ginseng Induced Genetic Signature in 
Human Primary Immune Cells 
 
2.1 Statement of Contribution 
This manuscript was submitted to the Journal of Ethnopharmacology on December 8 
2011 with authorship as follows, Holly R. Lemmon, Jane Sham, Luan Chau and Joaquín 
Madrenas. As first author my scientific contributions to this manuscript were completing 
all the data on the induction of cytokines IL-6, IL-1β, TNF-α, IL-10, IFN-γ, IL-12P40, 
IL12-P70 and IL-23 by PBMC and monocytes. I also completed all of the data on the 
effect of the North American ginseng extracts on LPS and SEE as well as all of the 
fractionation data including the induction of IL-6, and the effect of the fractions on the 
LPS and SEE responses of PBMC.  
 
2.2 Abstract 
Ethnopharmacological relevance: Ginseng (GS) has played a pivotal role in traditional 
Chinese medicine for thousands of years. Its use has become increasingly popular in 
North America, in part due to the many claims of its immune-enhancing properties. The 
immunopharmacology of the North American variety of GS and its extracts is needed to 
substantiate these claims.  
Materials and Methods: Human peripheral blood mononuclear cells were exposed to 
different North American GS extracts and microarray analysis was performed. The 
profile of cytokine response to GS extracts was established by ELISA, and Ingenuity 
Pathway Analysis was used to identify potential signaling pathways responsible for the 
transcriptional profile induced by GS. Fractionation of the aqueous and polysaccharide 
extracts was done to determine the molecular weight of the active immune modulatory 
ingredient(s).  
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Results: We found that GS induced a transcriptional profile of immunomodulation 
characterized by a net Th1 immune response, with up-regulation of multiple pro-
inflammatory cytokines (e.g., IFN-γ, IL-23A and IL-6) and down-regulation of TGF-β, 
IL-13 and the LPS co-receptor CD14. Ingenuity Pathway Analysis (IPA) revealed that 
the MAPK (ERK-1/2), PI3K, p38 and NF-κB cascades were key signalling pathways 
through which GS may trigger its immunomodulatory action. Furthermore, induction of 
such an immunomodulatory signature was recapitulated with the high molecular weight 
polysaccharides found in aqueous and polysaccharide GS extracts. 
Conclusions: Based on our results, we conclude that high molecular weight 
polysaccharides in North American GS aqueous and polysaccharide extracts likely 
modulate the MAPK (ERK-1/2), PI3K, p38 and NF-κB signalling pathways in PBMC 
resulting in the induction of a Th1 transcriptional profile. Our results may assist in 
optimizing GS-mediated immunomodulation and focus the search for compounds in GS 
extracts with specific immunomodulatory activities. 
 
2.3 Introduction 
Ginseng (GS) is the name given to several species of perennial plants that produce berry-
like flowers and fleshy roots. The two most commonly recognized species of GS are the 
Asian GS Panax ginseng and the North American GS Panax quinquefolius 1, 2. Asian GS 
is regularly consumed as an ingredient in tea, alcoholic beverages or candy 3. GS has also 
been an important part of traditional Chinese herbal remedies for thousands of years 1, 2 
due to claimed health benefits such as enhancement of immunity, stress relief and 
prevention of aging 4, 5.  
The current use of GS extends beyond Asia. In 2002, 4–5% of Americans aged 45–64 
years of age, accounting for approximately 13 million individuals, used GS as a herbal 
supplement 6. In North America, GS has become the second-highest selling herbal 
supplement; in 2000, GS had gross retail sales of nearly $62 million 7. In Canada, 17–
32% of patients with cardiovascular disease reported use of alternative supplements and 
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6% of those using herbs reported GS use 8. Additionally, GS is the 10th most used herbal 
supplement in HIV patients, accounting for 34% of individuals studied 9.  With growing 
interest in the Western market for herbal medicine, an increasing amount of attention has 
focused on North American GS 10. 
Despite the wide use of North American GS, the mechanism of action and the effects of 
specific extracts from this root remain mostly unknown. The biological effects of GS 
have generally been attributed to ginsenosides, low molecular weight saponins found in 
GS 2.  For example, ginsenosides have been shown to have anti-tumour and oxidative-
stress prevention properties 5, 11-14. However, it is unclear if the immune effects of GS are 
due to ginsenosides or to other components in GS. In particular, polysaccharides isolated 
from GS, such as poly-furanosyl-pyranosyl-saccharides and monosaccharide have been 
claimed to have immune-enhancing effects 15, 16, justifying the use of preparations such as 
COLD-FX®, which contains 80% of poly-furanosyl-pyranosyl-saccharides from North 
American GS 15, and marketed to prevent upper respiratory tract infections 17. 
To explore the immunomodulatory capacity of distinct North American GS extracts, we 
examined the profile of gene expression induced on human peripheral blood mononuclear 
cells (PBMC) by water-soluble GS (P. quinquefolius) fractions (i.e. aqueous extracts of 
GS equivalent to tea-like preparations of GS). We found that aqueous GS extracts induce 
a transcriptional profile characterized by an enhanced innate and adaptive Th1 pro-
inflammatory immune response - a profile corroborated at the protein level. These 
changes were induced mostly by high molecular weight fractions of polysaccharide 
extracts of North American GS. 
 
2.4 Materials and Methods 
2.4.1 Cells 
Informed consent from all individuals was obtained in compliance with the Office of 
Research Ethics at the University of Western Ontario. Ficoll-Hystopaque density gradient 
centrifugation was used to isolate human PBMC from healthy volunteers. Cells were 
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cultured in RPMI-1640, supplemented with 10% FCS, 1% L-glutamine, 1% 
penicillin/streptomycin, 1% MEM non essential amino acids, 1% 1M Hepes and 1% 
sodium pyruvate. 
2.4.2 Preparation of North American GS extracts 
 Roots of Panax quinquefolius were collected from 7 different farms in Southwestern 
Ontario, Canada. Samples were ground and soaked three times for five hours in water or 
an ethanol/water (75/25, v/v) solution at 40 °C. The solutions were then filtered and 
excess solvent was removed in a rotavaporizer under vacuum at 45 °C. Powdered 
aqueous extracts (10 g) were dissolved in 10 mL of distilled water. Four volumes of 95% 
ethanol were added to the solution in order to precipitate crude polysaccharides. 
Polysaccharide precipitate was collected by centrifugation (3000 rpm for 10 minutes) and 
freeze dried at -50 °C under reduced pressure. The crude polysaccharide (1 g) was re-
dissolved in distilled water (10 mL) and treated with Sevag reagent (1:4 n-
butanol:chloroform, v/v, 40 mL) to remove proteins. After re-precipitation by ethanol and 
freeze-drying, a final polysaccharide fraction was obtained. The content of these extracts 
has been previously described 18. These different types of North American GS extracts 
and their fractions were used throughout this work and are referred to as GS extracts or 
corresponding fractions. Lipopolysaccaride (LPS) contamination of GS extracts was 
ruled out by the Limulus test and further ensured by treatment with Polymyxin B. 
2.4.3 Preparation of GS extracts fractionated according to molecular 
weight 
Twenty mg of powdered GS extracts were dissolved in 1 mL of colourless media. Five 
hundred µL of GS extract at 20 mg/mL was placed in a 100 kDa Millipore Centrifugal 
Filter Unit (Billerica, MA). The filtrate was then put into centrifugal filter units with 
sequentially lower molecular weight cut offs (50 kDa, 30 kDa and 10 kDa). 50µL of 
colourless media was used to wash each filter and remove any precipitate. 
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2.4.4 Reagents 
COLD-FX was purchased from commercial sources (Afexa Life Sciences Inc. 
Mississauga, ON). According to manufacturer’s description, it contains CVT-E002, a 
proprietary ChemBioPrint® (CBP®) product of greater than 80% poly-furanosyl-
pyranosyl-saccharides extracted by an aqueous method from Panax quinquefolius. 
Staphylococcal aureus enterotoxin E (SEE) was purchased from Toxin Technologies 
(Sarasota, FA). Escherichia coli lipopolysaccharide (LPS), phorbol 12-myristate 13-
acetate (PMA) and ionomycin were purchased from Sigma-Aldrich (St. Louis, MO).  
2.4.5 Functional assays 
Human PBMC (2 x 105 cells) in 200 µL of media per well in 96-well U-bottom plates 
(Nunc, Rochester, NY) were stimulated for 20 hours with increasing concentrations of up 
to 200 µg/mL of GS extracts or COLD-FX, by themselves or in the presence of LPS or 
SEE. Quantification of IL-1β, IL-6, IL-10, TNF-α, IFN-γ, IL-12p40, IL-12p70, IL-23 and 
IL-2 was performed using human OptEIA™ ELISA kits (BD Biosciences, San Diego, 
CA). 
2.4.6 Monocyte Isolation  
CD14+ monocyte isolation was performed using MACS human monocyte positive 
isolation kit (Miltenyi Biotec, Auburn, CA). CD14+CD16+ monocyte isolation was 
performed using EasySep negative selection kit (Stemcell Technologies, Vancouver, 
BC). Monocytes were then counted and plated at 50,000 cells in 200 µL of media per 
well in 96-well U bottom plates and were stimulated with increasing concentrations of 
GS extracts or COLD-FX for 20 hours.  
2.4.7 Microarray Analysis 
Total RNA from cells of two independent donors was isolated using a Qiagen kit 
(Qiagen, Valencia, CA) and used to generate cDNA. cDNA samples were hybridized to 
the Affymetrix GeneChip Human Gene 1.0 sense target Array (Affymetrix, Santa Clara, 
CA). Expression levels were converted to fold changes by comparing expression levels 
between treatment and control sample arrays (Partek Incorporated, St. Louis, MO). Genes 
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with a fold change less than 2 were filtered and eliminated from analysis. Profiled 
clusters of genes were identified and correlated to functional effects using Partek 
software (Partek Incorporated).  
2.4.8 Ingenuity Pathway Analysis (IPA) 
Affymetrix microarray data was analysed using the IPA program that identifies 
relationships, mechanisms, functions, and pathways of biological relevance that are most 
significantly perturbed in a given dataset (Ingenuity Systems, Redwood City, CA). 
2.4.9 Flow cytometry 
FITC-labelled anti-CD14 antibodies were used to assess CD14 expression on the cell 
surface by flow cytometry. FITC-labelled anti-mouse IgG1κ antibodies were used as 
isotype controls.  
2.4.10 Statistical Analysis 
Graphpad Prism (Graphpad Instat Software Inc., San Diego, CA), was used to perform 
ANOVA with post-hoc Bonferroni tests to determine the statistical significance of 
differences among groups. Probability values of P < 0.05 were considered significant. 
 
2.5 Results  
2.5.1 Aqueous and polysaccharide extracts of North American GS 
induce a broad profile of cytokine production 
To start identifying the immunomodulatory effects of GS we first measured the effect of 
the different North American GS extract formulations on immune cell activation, using 
induction of cytokine production as a read-out. We found that GS extracts induced the 
production of IL-6, IL-1β, TNF-α and IL-10 by human PBMC in a dose-dependent 
manner (Fig. 2.1). However, there was a marked difference in the magnitude of this effect 
between different types of GS extracts. Aqueous and polysaccharide extracts induced 
significantly more cytokine production than the ethanol extract (P < 0.001) (Fig. 2.1). 
COLD-FX, used as a control, induced a similar profile of cytokine production as the 
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aqueous and polysaccharide extracts. The cytokine response induced by GS extracts was 
corroborated using extracts prepared from seven different GS farms (Fig. 2.1). 
Furthermore, this response was not due to LPS contamination because no endotoxin was 
detected with the Limulus test and the cytokine response was resistant to polymyxin B 
(data not shown).  
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Figure 2.1 
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Figure 2.1. - Cytokine response of human PBMC to aqueous, polysaccharide and 
ethanol GS extracts from 7 different North American GS farms. Human PBMC were 
stimulated with increasing concentrations of COLD-FX  (top row graphs) or of aqueous 
(▲), polysaccharide (▼) and ethanol ( ) extracts derived from the roots of North 
American GS plants obtained from 7 different farms for 20h. IL-1β, IL-6, TNF-α and IL-
10 in the supernatants were measured by ELISA. Data represent mean and standard 
deviation of triplicates, and are representative of 3 independent experiments. Differences 
between responses to aqueous or polysaccharide extracts vs. ethanol extracts were 
significant as determined by two-way ANOVA (P < 0.001).  
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To determine the contribution of monocytes to the pro-inflammatory IL-6 response of 
PBMC to GS, two monocyte subsets were isolated. CD14+ monocytes make up the 
majority of monocytes, approximately 90% in peripheral blood, the other 10% being the 
highly pro-inflammatory CD14+CD16+ monocytes, which have a higher potency of 
antigen presentation than preparations of monocytes based on CD14+ expression only 19. 
Interestingly, we found no significant difference between the amounts of IL-6 produced 
by either monocyte subset in response to GS extracts (Fig. 2.2a and 2.2b) but both 
monocyte subsets produced significantly less (P < 0.05) IL-6 in response to the aqueous 
or polysaccharide extract than PBMC with the same treatments. Interestingly, such a 
difference was lost when using COLD-FX® (Fig. 2.2C), suggesting that the IL-6 response 
to the GS extracts involves a different set of mechanisms.  
Next, we tested whether the different GS extracts could inhibit the response to LPS. We 
observed that neither the GS extracts (polysaccharide, aqueous or ethanol) from 7 
different GS farms nor COLD-FX® caused any change in the immune response to LPS as 
measured by IL-6 production (Fig. 2.3). This lack of effect was observed across a wide 
range of LPS and extract concentrations, suggesting that it was not due to saturation of 
the LPS response.  
To further characterize the immune properties of GS extracts we examined the effects of 
these extracts on the T cell response to superantigens. Superantigens such as SEE activate 
up to 20% of peripheral blood T cells as illustrated by an increase in IL-2 production 20 
(Fig. 2.4). The addition of aqueous or polysaccharide GS extracts during SEE-induced T 
cell activation resulted in significant (P < 0.05) down regulation of the IL-2 response 
(Fig. 2.4). This effect was not significant for the ethanol extracts. Furthermore, such an 
activity was consistently seen across extracts from the seven GS farms tested.  
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Figure 2.2 
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Figure 2.2. – IL-6 responses of PBMC, CD14+ monocytes and CD14+CD16+ 
monocytes to GS extracts and COLD-FX. Human PBMC ( ), CD14+ monocytes 
(▲) and CD14+CD16+ monocytes (●) from the same donor were stimulated with 
increasing concentrations of (A) aqueous GS extract, (B) polysaccharide GS extract and 
(C) COLD-FX for 20h. IL-6 accumulation in culture supernatants were measured by 
ELISA. Data represent mean and standard deviation of triplicates. Differences between 
the responses of CD14+ and CD14+CD16+ monocytes were significantly different from 
those of PBMC as determined by two-way ANOVA *: P < 0.05, **: P < 0.01, ***: P < 
0.001. 
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Figure 2.3 
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Figure 2.3. - Aqueous, polysaccharide and ethanol GS extracts do not inhibit the 
innate immune response to LPS. Human PBMC were stimulated with increasing 
concentrations of LPS alone () or in the presence of 150 µg/mL aqueous (▲), 
polysaccharide (▼) and ethanol ( ) GS extracts from 7 different farms or COLD-FX  
(●) for 20h. IL-6 accumulation in culture supernatants was measured by ELISA. Data 
represent mean and standard deviation of triplicates.  
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Figure 2.4 
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Figure 2.4. - Aqueous and polysaccharide GS extracts down-regulate the IL-2 
response to S. aureus superantigens (SEE). Human PBMC were stimulated with 
increasing concentrations of SEE alone () and with 150 µg/mL of aqueous (▲), 
polysaccharide (▼) and ethanol ( ) GS extracts from 7 different farms or COLD-FX      
(●) for 20h. IL-2 accumulation in culture supernatants was measured by ELISA. Data 
represent mean and standard deviation of triplicates. Differences between GS extracts or 
COLD-FX and the SEE alone group were significantly different as determined by one-
way ANOVA.  *: P < 0.05, **: P < 0.01, ***: P < 0.001.  
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2.5.2 Transcriptional profile induced by aqueous extracts of North 
American GS. 
To broadly characterize the response of PBMC to an aqueous GS extract we performed 
microarray analysis of this response. After exclusion of genes with a less than a 2 fold 
change over baseline, we found that 104 genes were up-regulated and 53 genes were 
down-regulated in response to the aqueous GS extract. Bioinformatics analysis of these 
genes revealed a transcriptional profile of immunomodulation (Tables 2.1 and 2.2). IFN-γ 
gene, coding for the primary Th1 cytokine, was found to be the most up-regulated gene in 
response to GS. Formyl peptide receptor 3 (FPR3) was the most down-regulated gene. 
An overwhelming number of the regulated genes coded for cytokines, chemokines, or 
were genes required for proper immune function. These results were replicated in 
genetically unrelated donors and broad similarities in the heat map profile were detected 
in those donors (data not shown). 
To control for the quality of the DNA microarray results, we examined the changes at the 
protein level for some of the most significantly regulated genes. As predicted by the 
microarray data, we found that IFN-γ, IL-12p40 and IL-23 were up-regulated by COLD-
FX®, and the aqueous and polysaccharide GS extracts compared to ethanol GS extract 
(Fig. 2.5). CD-14 was identified in the microarray to be down-regulated and this down-
regulation was confirmed at the protein level by flow cytometry. After 30 minutes (data 
not shown) and 4 hours of incubation with the aqueous GS extract or COLD-FX®, there 
was a significant decrease (P < 0.05) in expression levels of cell surface-CD14, measured 
by mean fluorescents intensity (MFI) (Fig. 2.6).  
Next, we studied the molecular relationship of the top 20 up-regulated genes identified in 
the microarray analysis using Ingenuity Pathway Analysis (IPA). IPA generated a 
molecular network identifying which biological pathways were most greatly perturbed by 
those genes (Fig. 2.7). This resulted in the identification of several signalling molecules 
as being involved in the immune response to an aqueous GS extract including p38 
MAPK, PI3K (complex), NF-κB (complex) and ERK 1/2.   
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Table 2.1: Up-regulated Genes in Human PBMC in response to an Aqueous GS 
Extract 
Rank Gene 
Symbol 
NCBI Reference 
Sequence ID 
Description Fold Change 
Range of 
Up-
regulation 
1 IFNG NM_000619  interferon, gamma  53.2 – 55.9 
2 MMP1 NM_002421 matrix metallopeptidase 1 (interstitial collagenase) 14.3 - 16.7 
3 MMP10 NM_002425 matrix metallopeptidase 10 (stromelysin 2)  12.5 – 13.0 
4 CXCL9 NM_002416 chemokine (C-X-C motif) ligand 9  7.5 – 23.1 
5 CXCL10 NM_001565 chemokine (C-X-C motif) ligand 10  5.6 – 11.0 
6 CSF2 NM_000758 colony stimulating factor 2 (granulocyte-macrophage 4.9 - 5.3 
7 CSF3 NM_172220 colony stimulating factor 3 (granulocyte)  5.2 – 8.6 
8 IL1F9 NM_019618 interleukin 1 family, member 9  5.2 – 23.5 
9 IL24 NM_006850 interleukin 24, transcript variant 1 4.7 – 8.5 
10 IL23A NM_016584 interleukin 23, alpha subunit p19  4.2 – 6.7 
11 IL20 NM_018724 interleukin 20  2.8 - 3.8 
12 F3 NM_001993 coagulation factor III (thromboplastin, tissue factor) 3.7 – 18.2 
13 IFIT1 NM_001548 interferon-induced protein with tetratricopeptide repeats 1 3.7 – 15.6 
14 MIR146A NR_029701 microRNA 146a (MIR146A), microRNA 3.6 – 5.5 
15 IL6 NM_000600 interleukin 6 (interferon, beta 2)  3.5 – 5.1 
16 INHBA NM_002192 inhibin, beta A  3.5 – 20.2 
17 TNF NM_000594 tumor necrosis factor  3.3 – 3.4 
18 IFIT2 NM_001547 interferon-induced protein with tetratricopeptide repeats 2 3.3 – 8.0 
19 RNF152 NM_173557 ring finger protein 152  2.0 - 3.2 
20 TNFSF15 NM_005118 tumor necrosis factor (ligand) superfamily, member 15 3.2 – 8.5 
21 RHCG NM_016321 Rh family, C glycoprotein  3.2 – 9.1 
22 STOM NM_004099 stomatin, transcript variant 1 2.9 - 3.1 
23 IFIT3 NM_001031683 interferon-induced protein with tetratricopeptide repeats 3 3.1 – 10.2 
24 HERC5 NM_016323 hect domain and RLD 5  3.1 – 11.1 
25 RTP4 NM_022147 receptor (chemosensory) transporter protein 4 3.1 – 4.8 
26 MIR221 NR_029635 microRNA 221, microRNA  3.0 – 3.9 
27 GJB2 NM_004004 gap junction protein, beta 2, 26kDa  3.0 – 9.4 
28 CXCL2 NM_002089 chemokine (C-X-C motif) ligand 2  3.0 – 5.0 
29 OAS3 NM_006187 2'-5'-oligoadenylate synthetase 3, 100kDa  3.0 – 9.6 
30 RSAD2 NM_080657 radical S-adenosyl methionine domain containing 2 3.0 – 17.2 
31 MX1 NM_002462 myxovirus (influenza virus) resistance 1, in interferon-
inducible protein p78 (similar to mouse) 
3.0 – 8.1 
32 MIR155 NR_030784 microRNA 155, microRNA 3.0 – 6.7 
33 IL1R1 NM_000877 interleukin 1 receptor, type I  2.9 – 8.2 
34 GEM NM_005261 GTP binding protein overexpressed in skeletal muscle 2.9 – 4.0 
35 IFI35 NM_005533 interferon-induced protein 35  2.8 – 5.8 
36 C13orf29 NR_027701 chromosome 13 open reading frame 29  2.7 – 3.1 
37 USP18 NM_017414 ubiquitin specific peptidase 18  2.7 - 14.7 
38 TFPI2 NM_006528 tissue factor pathway inhibitor 2 (TFPI2 2.7 - 5.4 
39 CD69 NM_001781 CD69 molecule, transcript variant 1 2.7 – 3.2 
40 USP18 NM_017414 ubiquitin specific peptidase 18  2.7 – 11.4 
41 DHX58 NM_024119 DEXH (Asp-Glu-X-His) box polypeptide 58  2.6 – 5.5 
42 SPINK1 NM_003122 serine peptidase inhibitor, Kazal type 1  2.6 – 4.5 
43 CXCL11 NM_005409 chemokine (C-X-C motif) ligand 11  2.6 – 17.1 
44 CFB NM_001710 complement factor B  2.6 – 13.5 
45 BST2 NM_004335 bone marrow stromal cell antigen 2  2.6 – 3.6 
46 PNPT1 NM_033109 polyribonucleotide nucleotidyltransferase 1  2.6 – 7.7 
47 IFI44 NM_006417 interferon-induced protein 44  2.6 – 8.6 
48 GPRC5A NM_003979 G protein-coupled receptor, family C, group 5, member A 2.5 – 4.9 
49 CFB NM_001710 complement factor B  2.5 – 12.7 
50 OAS1 NM_016816 2',5'-oligoadenylate synthetase 1, 40/46kDa  2.5 – 6.2 
51 PRIC285 NM_001037335 peroxisomal proliferator-activated receptorA interacting 
complex 285 
2.5 – 3.9 
52 HSH2D NM_032855 hematopoietic SH2 domain containing  2.5 – 2.1 
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53 STAT2 NM_005419 signal transducer and activator of transcription 2, 113kDa 2.5 – 3.2 
54 LY6E NM_002346 lymphocyte antigen 6 complex, locus E  2.5 – 5.1 
55 DDX58 NM_014314 DEAD (Asp-Glu-Ala-Asp) box polypeptide 58  2.5 – 5.4 
56 PGAP1 NM_024989 post-GPI attachment to proteins 1  2.5 – 3.9 
57 ZBP1 NM_030776 Z-DNA binding protein 1 (ZBP1),  2.4 – 2.5  
58 HERC6 NM_017912 hect domain and RLD 6  2.4 – 8.5 
59 PMAIP1 NM_021127 phorbol-12-myristate-13-acetate-induced protein 1 2.4 – 4.0 
60 GBP5 NM_052942 guanylate binding protein 5 2.4 – 4.1 
61 CXCL3 NM_002090 chemokine (C-X-C motif) ligand 3 2.4 – 3.3 
62 PARP9 NM_031458 poly (ADP-ribose) polymerase family, member 9 2.4 – 5.4 
63 IFI44L NM_006820 interferon-induced protein 44-like  2.4 – 9.6 
64 PRKD2 NM_016457 protein kinase D2 2.3 – 2.1 
65 IFIH1 NM_022168 interferon induced with helicase C domain 1  2.3 – 5.8 
66 ISG20 NM_002201 interferon stimulated exonuclease gene 20kDa 2.3 – 2.9  
67 LIF NM_002309 leukemia inhibitory factor (cholinergic differentiation 
factor) 
2.1 – 2.3 
68 IRF7 NM_004031 interferon regulatory factor 7 2.3 – 2.5 
69 PRF1 NM_005041 perforin 1 (pore forming protein),  2.1 – 2.3 
70 SLC38A5 NM_033518 solute carrier family 38, member 5  2.3 – 2.9 
71 TM4SF1 NM_014220 transmembrane 4 L six family member 1  2.3 – 4.7 
72 CFB NM_001710 complement factor B  2.3 – 9.1 
73 RASGRP3 NM_170672 RAS guanyl releasing protein 3 (calcium and DAG-
regulated) 
2.3 – 4.0 
74 SLC4A10 NM_001178015 solute carrier family 4, sodium bicarbonate transporter, 
member 10 
2.3 – 3.4 
75 GNG2 NM_053064 guanine nucleotide binding protein (G protein), gamma 2 2.3 – 2.5 
76 AREG NM_001657 amphiregulin  2.2 – 3.6 
77 PPM1K NM_152542 protein phosphatase, Mg2+/Mn2+ dependent, 1K 2.2 – 3.3 
78 AREG NM_001657 amphiregulin  2.2 – 4.1 
79 MX2 NM_002463 myxovirus (influenza virus) resistance 2 (similar to mouse) 2.2 – 4.7 
80 EPSTI1 NM_001002264 epithelial stromal interaction 1 (breast) 2.2 – 7.0 
81 APOL1 NM_145343 apolipoprotein L, 1  2.2 – 3.4 
82 TXN NM_003329 thioredoxin (TXN 2.2 – 6.2 
83 CCNA1 NM_003914 cyclin A1 (CCNA1), transcript variant 1,  2.2 – 3.5 
84 EREG NM_001432 epiregulin  2.2 – 3.9 
85 MOV10 NM_020963 Mov10, Moloney leukemia virus 10, homolog (similar to 
mouse) 
2.2 – 2.6 
86 PARP14 NM_017554 poly (ADP-ribose) polymerase family, member 14 2.2 – 3.7 
87 DDX60 NM_017631 DEAD (Asp-Glu-Ala-Asp) box polypeptide 60  2.1 – 6.6 
88 CMPK2 NM_207315 cytidine monophosphate (UMP-CMP) kinase 2, 
mitochondrial 
2.1 – 7.8 
89 RGS1 NM_002922 regulator of G-protein signaling 1  2.1 – 2.9 
90 TDRD7 NM_014290 tudor domain containing 7  2.1 – 4.2 
91 CCL3 NM_002983 chemokine (C-C motif) ligand 3  2.1 – 4.3 
92 OASL NM_003733 2'-5'-oligoadenylate synthetase-like  2.1 – 3.9 
93 TMEM140 NM_018295 transmembrane protein 140  2.1 – 2.4 
94 OAS2 NM_002535 2'-5'-oligoadenylate synthetase 2, 69/71kDa  2.1 – 4.3 
95 SLFN12L NM_001145027 sapiens schlafen family member 12-like  2.0 – 2.1 
96 PML NM_033240 promyelocytic leukemia  2.1 – 3.3 
97 FNIP2 NM_020840 folliculin interacting protein 2  2.1 – 4.6 
98 DUSP5 NM_004419 dual specificity phosphatase 5  2.1 – 2.6  
99 STAP1 NM_012108 signal transducing adaptor family member 1  2.1 – 4.4 
100 CCL20 NM_004591 chemokine (C-C motif) ligand 20  2.0 – 12.0 
101 LAMP3 NM_014398 lysosomal-associated membrane protein 3  2.0 – 4.2 
102 CCRN4L NM_012118 CCR4 carbon catabolite repression 4-like (S. cerevisiae) 2.0 – 3.8  
103 CHRNA6 NM_004198 cholinergic receptor, nicotinic, alpha 6  2.0 – 3.3 
104 TNFRSF9 NM_001561 tumor necrosis factor receptor superfamily, member 9 2.0 – 3.2 
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Table 2.2: Down-regulated Genes in Human PBMC in response to an Aqueous GS 
Extract 
Rank Gene 
Symbol 
NCBI Reference 
Sequence ID 
Description Fold Change 
Range of 
Down-
regulation 
1 FPR3 NM_002030 formyl peptide receptor 3  -13.4 – -10.8 
2 GAPT NM_152687 GRB2-binding adaptor protein, transmembrane  -6.3 – -5.3 
3 CCR2 NM_001123396 chemokine (C-C motif) receptor 2  -7.0 – -6.2 
4 CSF1R NM_005211 colony stimulating factor 1 receptor  -18.3 – -6.1 
5 STEAP4 NM_024636 STEAP family member 4  -6.0 – -3.8 
6 VCAN NM_004385 versican (VCAN), transcript variant 1,  -13.8 – -5.9 
7 LILRA2 NM_001130917 leukocyte immunoglobulin-like receptor, subfamily A (with TM 
domain), member 2 
-5.2 – -4.6 
8 TGFBI NM_000358 transforming growth factor, beta-induced, 68kDa -4.9 – -4.8 
9 LILRA1 NM_006863 leukocyte immunoglobulin-like receptor, subfamily A (with TM 
domain), member 1 
-4.6 – -3.7 
10 CCR2 NM_001123041 chemokine (C-C motif) receptor 2  -5.4 – -4.1 
11 CCR1 NM_001295 chemokine (C-C motif) receptor 1  -3.8 – -2.7 
12 CCL24 NM_002991 chemokine (C-C motif) ligand 24  -6.3 – -3.4 
13 LRRC25 NM_145256 leucine rich repeat containing 25  -3.6 – -3.5  
14 FN1 NM_212482 fibronectin 1 (FN1), transcript variant 1 -4.4 – -3.6 
15 PLXDC2 NM_032812 plexin domain containing 2  -3.6 – -3.0 
16 CD14 NM_000591 CD14 molecule (CD14), transcript variant 1 -4.2 – -3.3 
17 MPEG1 NM_001039396 macrophage expressed 1   -3.3 – -2.5 
18 LILRB1 NM_006669 leukocyte immunoglobulin-like receptor, subfamily B (with TM 
and ITIM domains), member 1 
-3.0 – -2.8 
19 PECAM1 NM_000442 platelet/endothelial cell adhesion molecule  -4.5 – -3.0 
20 SLC8A1 NM_021097 solute carrier family 8 (sodium/calcium exchanger), member 1 -3.2 – -2.9 
21 PPARG NM_138712 peroxisome proliferator-activated receptor gamma -3.3 – -2.7 
22 CTNND1 NM_001085458 catenin (cadherin-associated protein), delta 1 -2.7 – -2.3 
23 HMOX1 NM_002133 heme oxygenase (decycling) 1  -3.4 – -2.7 
24 MIR223 NR_029637 microRNA 223, microRNA  -2.7 – -2.3 
25 TNS1 NM_022648 tensin 1  -7.1 – -2.7 
26 CMKLR1 NM_001142343 chemokine-like receptor 1  -2.7 - -2.6 
27 C17orf60 NM_001085423 chromosome 17 open reading frame 60  -2.6 – -2.5 
28 CXCL16 NM_022059 chemokine (C-X-C motif) ligand 16  -2.6 – -2.5 
29 ENG NM_000118 endoglin (ENG), transcript variant 2 -4.2 – -2.6 
30 GPNMB NM_001005340 glycoprotein (transmembrane) nmb  -9.9 – -2.6 
31 MAFB NM_005461 v-maf musculoaponeurotic fibrosarcoma oncogene homolog B 
(avian) 
-2.7 – -2.5 
32 IFI30 NM_006332 interferon, gamma-inducible protein 30  -2.5 – -2.4 
33 SIGLEC10 NM_033130 sialic acid binding Ig-like lectin 10  -2.5 – -2.2 
34 FAM198B NM_001128424 family with sequence similarity 198, member B -2.4 – -2.1 
35 ARHGAP18 NM_033515 Rho GTPase activating protein 18  -2.7 – -2.4 
36 CFP NM_002621 complement factor properdin (CFP -2.9 – -2.4 
37 CD300E NM_181449 CD300e molecule  -2.6 – -2.4 
38 VNN2 NM_004665 vanin 2, transcript variant 1  -2.8 – -2.4 
39 TM6SF1 NM_023003 transmembrane 6 uperfamily member 1  -2.4 – -2.3 
40 PLXNB2 NM_012401 plexin B2  -3.6 – -2.3 
41 NLRP12 NM_144687 NLR family, pyrin domain containing 12  -5.3 – -2.3 
42 CX3CR1 NM_001337 chemokine (C-X3-C motif) receptor 1  -2.7 – -2.3  
43 HIP1 NM_005338 huntingtin interacting protein 1  -3.1 – -2.3 
44 SLC37A2 NM_198277 solute carrier family 37 (glycerol-3- phosphate transporter), 
member 2 
-5.0 – -2.3 
45 CYP27A1 NM_000784 cytochrome P450, family 27, subfamily A, polypeptide 1 -6.3 – -2.2 
46 KIAA1598 NM_001127211 KIAA1598, transcript variant 1 -2.4 – -2.2 
47 KIAA1539 BC004406 KIAA1539 (cDNA clone MGC:10998 IMAGE:3) 2-.1 – -2.0 
48 EEPD1 NM_030636 endonuclease/exonuclease/phosphatase family domain containing 
1 
-4.4 – -2.1 
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49 CD300C NM_006678 CD300c molecule  -2.1 – -2.1 
50 SERPINE1 NM_000602 serpin peptidase inhibitor, clade E (nexin, plasminogen activator 
inhibitor type 1), member 1 
-3.0 – -2.1 
51 QSOX1 NM_002826 quiescin Q6 sulfhydryl oxidase 1  -2.5 – -2.2 
52 GLUL NM_002065 glutamate-ammonia ligase  -2.2 – -2.0 
53 CD9 NM_001769 CD9 molecule  -2.4 – -2.0 
 
2.5.3 The immunomodulatory effects of North American GS extracts 
are mediated by polysaccharides with a molecular weight higher 
than 100 kDa. 
Once we had determined the transcriptional profile induced by an aqueous North 
American GS extract, we proceeded to narrow down the identity of the compounds 
involved in this effect. To do this, whole aqueous and polysaccharide GS extracts were 
fractioned based on molecular weight. PBMC were then treated with different molecular 
weight fractions or fractioned extracts to determine the cytokine production induced by 
each fraction. We found that the profile of cytokine production, induced by whole 
aqueous or polysaccharide extracts was recapitulated when cells were stimulated with 
fractions containing compounds with a molecular weight greater than 100 kDa (Fig. 2.8A 
and 2.8B). The 0-10, 10-30, 30-50 and 50-100 kDa fractions produced significantly less 
(P < 0.01) IL-6 than the whole aqueous or polysaccharide extracts and the greater than 
100 kDa fraction.  
Consistent with these results, the greater than 100 kDa fraction of the aqueous GS 
extracts (Fig. 2.9A) and of the polysaccharide GS extracts (Fig. 2.9B) had similar 
properties as the whole extract, failing to change the response to LPS (data not shown), 
but significantly (P < 0.001) decreasing the IL-2 production in response to SEE by 
PBMC. Together, these data suggest that the active immunomodulatory component of GS 
extracts is a water-soluble polysaccharide of high molecular weight.  
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Figure 2.5 
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Figure 2.5. – IL-12, IL-23 and IFN-γ responses of PBMC to different GS extracts 
and COLD-FX. Human PBMC were stimulated with 150 µg/mL of aqueous, 
polysaccharide and ethanol GS extracts or COLD-FX, 100 ng/mL of LPS) or 50 ng/mL 
of PMA and 1mg/mL of ionomycin. IL-12p40, IL-12p70, IL-23 and IFN-γ accumulation 
in culture supernatants was measured by ELISA. Data represent mean and standard 
deviation of 3 independent experiments. Differences between cytokine production of 
control, COLD-FX and GS extracts was determined by one-way ANOVA, **: P < 0.01, 
***: P < 0.001.  
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Figure 2.6 
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Figure 2.6. – Aqueous GS extract decreases surface CD-14 expression. Human 
PBMC were stimulated for 4 hours with 200 µg/mL of aqueous extract (A) or COLD-
FX (B).  CD-14 expression was measured by flow cytometry using an isotype control 
(shaded histogram), no treatment (continuous line histogram in A and B), or treated with 
aqueous extract (dashed line histogram in A) or COLD-FX (dashed line histogram in 
B). Data represent mean and standard deviation of triplicates. Differences between 
responses to control and aqueous GS extract or COLD-FX were significant as 
determined by one-way ANOVA (P < 0.05).   
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Figure 2.7 
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Figure 2.7. – Ingenuity Pathway Analysis of the top 20 up-regulated genes after 
exposure to an aqueous GS extract. Shaded molecules indicate the genes that were 
directly up-regulated in response to aqueous extract. Unshaded molecules indicate genes 
inferred to be up-regulated upon treatment with aqueous extract.   
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Figure 2.8 
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Figure 2.8. – The immunomodulatory properties of aqueous and polysaccharide GS 
extracts are mediated by compounds with a molecular weight higher than 100 kDa. 
Human PBMCs were stimulated with increasing concentrations of fractionated aqueous 
extract (A) or polysaccharide extract (B) of MWs < 10 kDa (  ), 10 - 30 kDa (▲), 30 - 
50 kDa (▼), 50 - 100 kDa () and > 100 kDa (●) or whole extracts ( ) for 20h. IL-6 
concentration in culture supernatants was measured by ELISA. Data represent mean and 
standard deviation of triplicates and are representative of 2 independent experiments. **: 
P < 0.01; ***: P < 0.001. 
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Figure 2.9 
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Figure 2.9. – The “molecular weight greater than 100 kDa” fraction of aqueous and 
polysaccharide GS extracts recapitulate immunomodulation of T cells responses by 
aqueous and polysaccharide GS extracts. Human PBMC were stimulated with 0.1 
ng/mL of SEE in the absence or presence of 25 µg/mL of fractionated or whole aqueous 
extracts (A) or fractionated or whole polysaccharide extracts (B). IL-2 concentration in 
culture supernatants was measured by ELISA. Differences between responses to fractions 
or whole extract were significantly different from SEE alone as determined by one-way 
ANOVA *: P < 0.05, **: P < 0.01, ***:P < 0.001. 
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2.6 Discussion  
In this paper, we report that high molecular weight polysaccharides within aqueous North 
American GS extracts have significant immunomodulatory properties characterized by 
the induction of pro-inflammatory cytokines along a Th1 profile. Such a response results 
from broad transcriptional imprinting for immunomodulation. Based on bioinformatics 
analysis, North American GS immunomodulation is likely mediated by MAPK (ERK 
1/2), PI3K, p38 and NF-κB signalling, that leads to broad cytokine production including 
IL-6, IL-2, IL-1β, TNF-α, IFN-γ, IL-12 and IL-23. To our knowledge this work is the 
first to report the transcriptional profile of primary human immune cells in response to an 
aqueous North American GS extract.  
The molecules responsible for the immunomodulatory effects of GS have long been 
thought to be the low molecular weight steroidal saponins called ginsenosides 2, 3, 10, 21. 
However, it has been recently shown that polysaccharides in GS may also play a role 5, 11-
14
. Based on previous studies, the aqueous extract of GS contains a complex mixture of 
water-soluble components including polyacetylenic alcohols, ginsenosides and 
polysaccharides 18, 22 while the polysaccharide extract contains only the polysaccharides 
present in the aqueous extract. Fractionation of the aqueous or polysaccharide extracts by 
molecular weight allowed us to link immunomodulation with the high molecular weight 
fraction of GS. This fraction contains a complex mixture of polysaccharides with 
molecular weights greater than 100 kDa 23. In contrast, fractions containing 
polysaccharides of molecular weight less than 100 kDa had little immunomodulatory 
effects. These low molecular weight fractions likely contained ginsenosides as they have 
molecular weights between 5 and 15 kDa 24. Together, this reinforces the idea that 
immunomodulation is not primarily induced by ginsenosides.  
One interesting finding from this work is that the immunomodulatory properties of 
polysaccharides within North American GS extracts are not recapitulated by COLD-FX®, 
a preparation that contains 80% of poly-furanosyl-pyranosyl-saccharides from North 
American GS 15.  COLD-FX® induced less cytokine production by PBMC and had less 
effect on the IL-2 response of T cells stimulated with SEE than either the aqueous or 
polysaccharide extracts. It is possible that it is the complex mix of polysaccharides found 
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in the aqueous and polysaccharide GS extracts that have a broader profile of effects by 
acting on more cell types than COLD-FX®. This is suggested by the observation that the 
response to COLD-FX® was similar between both CD14+ and CD14+CD16+ isolated 
monocytes and PBMC. However, the response of monocytes to GS extracts was only half 
of the response observed with PBMC. While poly-furanosyl-pyranosyl-saccharides in 
COLD-FX® show immunomodulatory properties, there are other polysaccharides from 
GS that have shown immune effects, including panaxans, ginsan 25, arabinogalactans 26, 
rhamnogalacturonan II 27, galactose, arabinose, rhamnose, glucose, fucose and mannose 
22
. While the evidence points to a complex mixture of polysaccharides isolated from 
North American GS to be the active immunomodulatory compounds, further work is 
necessary to better understand exactly which polysaccharides and in what proportions 
may be most beneficial for immune modulation.   
The mechanism of action of GS polysaccharides is unknown. Many plant polysaccharides 
and phenols have been shown to bind to CD14 and TLR-4 28, 29 but this may be secondary 
to the presence of LPS. Of interest, CD14 was one of the molecules identified by our 
microarray experiments as being down-regulated in response to GS treatment, a result 
confirmed by flow cytometry. CD14 is a GPI-anchored membrane protein that acts as the 
main receptor for LPS together with TLR-4 and MD2 30. Down-regulation of surface 
CD14 may indicate modulation of this receptor upon interaction with GS or could be a 
secondary event following exposure to GS.  Our data suggest mostly the latter, occurring 
at the transcriptional level. In any case, this effect is not sufficient in vitro to decrease the 
response to LPS.  
Network analysis to determine the signalling pathways most perturbed by GS extracts 
suggested that the GS-induced immune modulation occurs through activation of the NF-
κB, PI3K, p38 and MAPK (ERK1/2) signalling pathways. These pathways are involved 
in the production of pro-inflammatory cytokines 31-33 and have previously been shown to 
be induced by GS extract stimulation in PBMC 34. In addition, these pathways are also 
involved in other biological activities of GS such as decreasing ischemic reperfusion 
injury 35, killing of tumours 36, 37 and reducing damage from oxidative stress 35. Similarly, 
PI3K signalling after GS treatment has been linked to the decrease of ischemic 
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reperfusion injury 5, 38 as well as to glucose uptake 39, 40. Activation of p38 and MAPK 
after treatment with GS has been implicated in inhibiting angiogenesis in human 
endothelial cells 41 as well as causing preferential apoptosis to cancer cells 42. Therefore, 
there seems to be a commonality of signalling events triggered by GS across different cell 
types.  
Among the genes up-regulated by GS, IFN-γ is the top one, coding for the primordial Th1 
cytokine IFN-γ. Of interest, while the IL-2 response of peripheral blood T cells to SEE 
was reduced by GS, the IFN-γ response was not.  This suggests that the IFN-γ response 
induced by GS extracts may come from sources other than activated T cells, likely NK 
cells. In this context, induction of a Th1 profile of immunity supports the claim to use GS 
extracts to combat respiratory viral infections, as it would enhance cellular immunity.  
It is important to note that the pro-inflammatory effect of GS extracts balanced with the 
induction of IL-10, an anti-inflammatory cytokine. Production of IL-10 may counteract 
the pro-inflammatory Th1 profile, and explain the findings of other groups that have 
reported a humoral Th2 response to GS exposure 23, 43. The magnitude of the IL-10 
response varies between extracts and this may explain the differences among reports.  
In summary, we show here that a complex mixture of high molecular weight 
polysaccharides present in water-soluble extracts of GS mediate most of the 
immunomodulatory properties of North American GS. These properties include the 
induction of a pro-inflammatory Th1 cytokine production profile and IL-10. This profile 
of response is determined by a strong immunomodulatory transcriptional signature 
secondary to signalling through the MAPK (ERK 1/2), PI3K, p38 and NF-κB pathways. 
Our work thus provides a comprehensive model for the immunomodulatory effects of 
North American GS extracts on primary human immune cells.  
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3 Biologically Active Ginsenosides Antagonize the 
Immunomodulatory Effects of North American Ginseng (Panax 
quinquefolius) Aqueous Extracts 
 
3.1 Statement of Contribution 
This manuscript will be submitted with authorship as follows, Holly R. Lemmon, Luan 
Chau, Dong-Shan An, Song-Gun Kim and Joaquín Madrenas. As first author my 
scientific contributions to this manuscript were completing all the experimental data 
contained in this manuscript. I also wrote the manuscript in full.  
 
3.2 Abstract 
Since its discovery, ginseng (GS) has been used in traditional Chinese medicine and has 
been claimed to have many benefits such as immune-enhancing properties. Historically, 
it has been proposed that ginsenosides, unique triterpenoid saponin molecules found only 
in ginseng, are responsible for GS’s immunomodulatory properties. Here we report that 
11 physiologically active ginsenosides and two ginsenoside mixtures by themselves 
induced little to no production of pro-inflammatory cytokines IL-6 and IL-1β in human 
PBMC. We also show that these ginsenosides antagonized the response of peripheral 
blood mononuclear cells (PBMC) to LPS by up to 32%. More importantly, the majority 
of these ginsenosides antagonized the immune activating effect of an aqueous GS extract 
and the modulatory activity of these extracts on the response to LPS and staphylococcal 
enterotoxin. Based on our results, we conclude that physiologically active ginsenosides 
have limited immunomodulatory capacity and, in fact, they can act as antagonists of the 
immune modulatory properties of North American GS aqueous extracts. Our results may 
provide an explanation for the paradoxical effects of GS in the literature due to the 
presence of different amounts of ginsenosides in the total GS extracts. These results may 
also assist in the optimization of GS preparations with maximum immunomodulatory 
properties.  
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3.3 Introduction 
The ginseng (GS) root has been used for thousands of years in traditional Chinese 
medicine and continues to play an important role in Asian culture. GS has been claimed 
to have many beneficial health effects including immune enhancement 1, 2. For this 
reason, GS has held its historic position in traditional Chinese medicine and is still widely 
used across Asia today. The use of GS is growing in North America. As of 2002, 
approximately 13 million men and women reported using GS 3, being the second-highest 
grossing herbal supplement in North America 4.   
Ginsenosides, low molecular weight saponins unique to the Panax genus of GS plants, 
including Asian (Panax ginseng) and North American (Panax quinquefolius) GS 5, 6, are 
one of the compounds found in GS. The two most common groups of ginsenosides are 
the protopanaxadiol and protopanaxatriol ginsenosides, each having a unique 4-trans ring 
steroidal backbone and differing in the type and location of sugars attached to the 
backbone 4. In protopanaxadiol ginsenosides, sugar moieties are attached to the β-OH at 
carbon 3 and/or carbon 20. Protopanaxatriol ginsenosides have sugars attached to the α-
OH at carbon 6 and/or the β-OH at carbon 20 7. The differential addition of different 
sugar side chains has resulted in the presence of over 100 unique ginsenosides. Upon 
ingestion, ginsenosides are deglycosylated by intestinal bacteria such as Bacteroides sp. 8, 
Bifidobacterium sp. 9, Bifidobacterium breve 10, Fusobacterium sp. 11, Lactobacillus 
delbrueckii 9, and Leuconostoc paramesenterioides 9 and these deglycosylated forms are 
the biologically active ginsenosides.  
The majority of research on the biological effects of GS has focused on ginsenosides and 
their metabolites as the molecules responsible for many of the functions ascribed to GS, 
including regulation of blood sugar, immunomodulation, anti-tumor effects and 
oxidative-stress prevention qualities 2, 12. For example, protopanaxatriol ginsenosides Re 
and Rg1 have been shown to increase the release of nitric oxide from endothelial cells 13. 
Compound K (C-K), a major metabolite of ginsenosides has been shown to stimulate 
insulin secretion and prevent the destruction of pancreatic islet cells 14. Also, Rh2 has 
been shown to inhibit tumour growth and induced tumour cells to undergo apoptosis 15. 
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However, no single study has assessed such a large number of different ginsenosides 
under the same conditions, and in their physiologically active form.  
In addition to ginsenosides, polysaccharides have also been proposed to have 
immunomodulatory properties. Polysaccharides isolated from ginseng have been shown 
to increase Th1 immune responses 16, inhibit tumour growth 17 and decrease the severity 
and duration of the common cold 18. Previous research has also shown that aqueous 
extracts of North American GS, which have both polysaccharides and ginsenosides, as 
well as polysaccharide extracts containing only polysaccharides isolated from the 
aqueous extract induce pro-inflammatory cytokine production 19. The aqueous and 
polysaccharide North American GS extracts have been shown to induce significant levels 
of IL-6, IL-1β and TNF-α as well as IL-10 as compared to the ethanol extract, composed 
mainly of ginsenosides 20. Also, the aqueous and polysaccharide GS extracts decreased 
IL-2 production by PBMC stimulated with superantigen, while the ethanol GS extract 
had no effect on IL-2 production by PBMC in the same treatment condition 20. Therefore, 
we wanted to determine the immunomodulatory effects of ginsenosides alone and in the 
presence of polysaccharides of GS.  
To examine the effects of purified, biologically active ginsenosides on 
immunomodulation, 11 single ginsenosides and two defined combinations of 
ginsenosides were tested in human peripheral blood mononuclear cells (PBMC). The 
immunomodulatory profile induced by these ginsenosides was established by examining 
their capacity to induce pro-inflammatory cytokines as well as their effect on the innate 
immune response to LPS and the adaptive T cell response to SEE. We also determined 
the properties of biologically active ginsenosides on the effect of North American GS 
aqueous or polysaccharide extracts on the innate and adaptive immune responses. We 
show that while ginsenosides did not induce high levels of cytokine production, they 
antagonized the induction of pro-inflammatory cytokines by the aqueous North American 
GS extract and down-regulated the innate immune response to LPS. However, these 
compounds did not antagonize the induction of pro-inflammatory cytokines by the 
polysaccharide GS extract. Furthermore, biologically active ginsenosides antagonized the 
effects of GS extracts on the immune responses to LPS and bacterial superantigens. The 
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profile of antagonism of biologically active ginsenosides on GS extracts suggests the 
presence of a common mechanistic step for these two projections and their 
immunomodulatory effects.  
 
3.4 Materials and Methods 
3.4.1 Cells 
Blood from healthy volunteers was used. Informed consent from all individuals was 
obtained in compliance with the Office of Research Ethics at the University of Western 
Ontario. Density gradient centrifugation with Ficoll-Hystopaque was used to isolate 
human PBMC. Cells were cultured in RPMI-1640, supplemented with 10% FCS, 1% L-
glutamine, 1% penicillin/streptomycin, 1% MEM non essential amino acids, 1% 1M 
Hepes and 1% sodium pyruvate. 
3.4.2 Preparation of Korean ginsenosides 
Ginsenosides Rb1, Rb2, Rc and Rd were purchased from Hongjiu Biotech Co., Ltd. 
Ginsenosides C-Mc1, C-K, C-Mc, C-O, C-Y, F2, Protopanaxadiol type (PPD), Rg3, Rh2, 
Gypenoside XVII (pure) (Gyp XVII), Gyp XVII (mixture), Gypenoside LXXV (pure) 
(Gyp LXXV) and Gyp LXXV (mixture) were prepared from Rb1, Rb2, Rh2 and Rd after 
digestion using Terrabacter sp. Gsoil 3082 β-glucosidase, Rhodanobacter sp. Gsoil 3054 
β-glucosidase, Rhodanobacter sp Gsoil 3054 α-arabinofuranosidase. As previously 
described, enzymatic reactions removed glucose(s) from carbon 3 to produce many 
different ginsenosides 21. Gyp XVII (mixture) is composed of Gyp XVII (pure), C-O, C-
Mc1 and F2. Gyp LXXV (mixture) is composed of Gyp LXXV (pure), C-Y, C-Mc and 
C-K.  
3.4.3 Preparation of North American GS extracts  
Roots of Panax quinquefolius were collected from a farm in Southwestern Ontario, 
Canada and extracts were prepared as previously described 20. The sample was ground 
and soaked three times for five hours in water at 40 °C. The solution was then filtered 
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and excess solvent was removed in a rotavaporizer under vacuum at 45 °C. Powdered 
aqueous extract (10 g) was dissolved in 10 mL of distilled water. Four volumes of 95% 
ethanol were added to the solution in order to precipitate crude polysaccharides. 
Polysaccharide precipitate was collected by centrifugation (3000 rpm for 10 minutes) and 
freeze-dried at reduced pressure. The crude polysaccharide (1 g) was re-dissolved in 
distilled water (10 mL) and treated with Sevag reagent (1:4 n-butanol:chloroform, v/v, 40 
mL) to remove proteins. After precipitation by ethanol and freeze-drying, the final 
polysaccharide fraction was obtained. LPS contamination of GS extracts was ruled out by 
the Limulus test and treatment with Polymyxin B. 
3.4.4 Reagents  
SEE was purchased from Toxin Technologies (Sarasota, Florida). LPS from E. coli was 
purchased from Sigma-Aldrich (St. Louis, Missouri). 
3.4.5 Functional assays 
PBMC (2 x 105 cells per well in triplicate and for each experimental group in 200 µL of 
media) were stimulated for 20 hours with increasing concentrations of ginsenosides and a 
single concentration of aqueous or polysaccharide GS extracts by themselves or in the 
presence of LPS or SEE. Culture supernatants were collected and quantification of IL-1β, 
IL-6 and IL-2 was performed using human eBioscience ELISA kits (San Diego, CA). 
3.4.6 Statistical Analysis 
Using Graphpad Prism (Graphpad Instat Software Inc., San Diego, CA), ANOVA with 
post-hoc Bonferroni tests were used to determine statistical significance of differences 
among groups. Probability values of P < 0.05 were considered significant. 
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3.5 Results  
3.5.1 Deglycosylated ginsenosides may induce low pro-inflammatory 
cytokine production. 
To characterize the immune properties of the different deglycosylated ginsenosides and 
ginsenosides mixtures we first measured their ability to induce the secretion of the 
prototypical pro-inflammatory cytokines (IL-1β and IL-6) by human PBMC. When 
PBMC were stimulated with each of the 13 ginsenosides tested, only three of the 13 
ginsenosides tested, C-Y, C-Mc and Gyp LXXV (pure), induced low but significant 
production of IL-1β (P < 0.001) (Fig. 3.1). In addition to these three ginsenosides, C-O 
and Gyp XVII (Mixture) also induced the production of IL-6 (Figure 3.2). These data 
suggest that some deglycosylated ginsenosides may induce the production of low levels 
of pro-inflammatory cytokines.  
 
3.5.2 Effect of deglycosylated ginsenosides on innate and adaptive 
immune responses of PBMC. 
Next, we studied the effects of deglycosylated ginsenosides on the innate immune 
response of PBMC to LPS. Exposure of PBMC to LPS induced a significant IL-6 
response (over 3700 pg mL-1). This response was partially but significantly (P < 0.001) 
inhibited by increasing concentrations of deglycosylated ginsenosides. (Up to 37% 
inhibition for some ginsenosides, (e.g.; Gyp LXXV (mixture), Gyp XVII (mixture) and 
Gyp LXXV (pure)) (Fig. 3.3). Of interest the modulatory effect of deglycosylated 
ginsenosides plateaued at 30-40% inhibition.  
To determine the effect of deglycosylated ginsenosides on adaptive immune responses, 
we used the T cell response to the Staphylococcal superantigen SEE. IL-2 production was 
used as an indicator of T cell activation. As expected, SEE induced a significant IL-2 
response of PBMC (Fig 3.4), and the addition of deglycosylated ginsenosides had no 
modulatory effect on this response. Together these data suggest that biologically active 
ginsenosides can partially inhibit the innate responses but do not affect the adaptive 
immune responses of human PBMC.  
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Figure 3.1 
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Figure 3.1. – IL-1β production by PBMC in response to deglycosylated ginsenosides. 
Human PBMC were stimulated with increasing concentrations of the indicated 
deglycosylated ginsenosides for 20 h. (A) C-Mc1 ( ), C-K (▲) and C-Mc (▼), (B) C-O 
(), C-Y (●) and Gyp LXXV (mixture) (), (C) Gyp XVII (mixture) ( ), Gyp LXXV 
(pure) ( ) and Gyp XVII (pure) ( ), (D) F2 ( ), PPD ( ), Rg3 ( ) and Rh2 ( ). 
Levels of IL-1β in culture supernatants were measured by ELISA. Data represent mean 
and standard deviation of three independent experiments performed in triplicate. 
Differences between IL-1β production by PBMC treated with 5 µg/mL and 0 µg/mL of 
ginsenoside were significantly different as determined by one-way ANOVA ***: (P < 
0.001). 
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Figure 3.2 
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Figure 3.2. – IL-6 production by PBMC in response to deglycosylated ginsenosides. 
Human PBMC were stimulated for 20 h with increasing concentrations of the indicated 
deglycosylated ginsenosides. (A) C-Mc1 ( ), C-K (▲) and C-Mc (▼), (B) C-O (), C-Y 
(●) and Gyp LXXV (mixture) (), (C) Gyp XVII (mixture) ( ), Gyp LXXV (pure)  
( ) and Gyp XVII (pure) ( ), (D) F2 ( ), PPD ( ), Rg3 ( ) and Rh2 ( ). Levels of 
IL-6 in culture supernatants were measured by ELISA. Data represent mean and standard 
deviation of three independent experiments performed in triplicate. Differences between 
IL-6 production by PBMC treated with 5 µg/mL and 0 µg/mL of ginsenoside were 
significantly different as determined by one-way ANOVA *: (P < 0.05), **: (P < 0.01), 
***: (P < 0.001). 
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Figure 3.3 
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Figure 3.3. – Deglycosylated ginsenosides partially blocked the IL-6 response of 
PBMC to LPS. Human PBMC were stimulated with 0.1 ng/mL of LPS and increasing 
concentrations of the indicated deglycosylated ginsenoside for 20 h. (A) C-Mc1 ( ), C-K 
(▲) and C-Mc (▼), (B) C-O (), C-Y (●) and Gyp LXXV (mixture) (), (C) Gyp XVII 
(mixture) ( ), Gyp LXXV (pure) ( ) and Gyp XVII (pure) ( ), (D) F2 ( ), PPD ( ), 
Rg3 ( ) and Rh2 ( ). Levels of IL-6 in culture supernatants were measured by ELISA. 
Data represent mean and standard deviation of three independent experiments performed 
in triplicate. Differences between responses to LPS and LPS with increasing 
concentrations of ginsenoside were significantly different as determined by one-way 
ANOVA **: (P < 0.01), ***: (P < 0.001). 
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Figure 3.4 
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Figure 3.4. – Degylcosylated ginsenosides modulate IL-2 responses of PBMC to SEE. 
Human PBMC were stimulated with 0.1 ng/mL of SEE and increasing concentrations of 
the indicated deglycosylated ginsenoside for 20 h. (A) C-Mc1 ( ), C-K (▲) and C-Mc 
(▼), (B) C-O (), C-Y (●) and Gyp LXXV (mixture) (), (C) Gyp XVII (mixture)  
( ), Gyp LXXV (pure) ( ) and Gyp XVII (pure) ( ), (D) F2 ( ), PPD ( ), Rg3 ( ) 
and Rh2 ( ). Levels of IL-2 in culture supernatants were measured by ELISA. Data 
represent mean and standard deviation of three independent experiments performed in 
triplicate.  
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3.5.3 Deglycosylated ginsenosides partially antagonized the PBMC 
response to North American GS aqueous extracts but not the 
response to polysaccharide extracts.  
Given the effect of deglycosylated GS extracts on the PBMC response, we looked at the 
effect of these ginsenosides on the PBMC response to aqueous or polysaccharide North 
American GS extracts. We and others19 have previously shown that aqueous and 
polysaccharide extracts of North American GS, which contain both ginsenosides and 
polysaccharides and only polysaccharides respectively, induce pro-inflammatory 
cytokine production. However, the polysaccharide extract, which contains only 
polysaccharides isolated from the aqueous extract, also induced pro-inflammatory 
cytokine production19 and we corroborated this effect for IL-1β (Fig. 3.5 and 3.6). When 
PBMC were stimulated with either extract and increasing concentrations of 
deglycosylated ginsenoside we observed that the all but Gyp XVII (mixture), Gyp LXXV 
(mixture) and Gyp LXXV (pure) partially blocked the IL-1β response induced by the GS 
aqueous extract on PBMC (Fig. 3.5). However, the deglycosylated ginsenosides had no 
effect on the response to the polysaccharide GS extract (Fig. 3.6).  
To corroborate the antagonism of these ginsenosides on the North American GS aqueous 
extracts, we tested the effect of these deglycosylated ginsenosides on the enhancement of 
the response to LPS by North American GS aqueous extracts. Aqueous North American 
GS extracts enhanced the PBMC response to LPS. When the aqueous extract was used 
with the degycosylated ginsenosides, the PBMC response to LPS was significantly 
decreased (Fig. 3.7). No biologically meaningful antagonism of deglycosylated 
ginsenosides on the North American GS polysaccharide extract was observed (Fig. 3.8). 
Together these results confirm that biologically active ginsenosides antagonize the 
aqueous North American GS extract.  
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Figure 3.5 
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Figure 3.5. – Deglycosylated ginsenosides antagonize the IL-1β response of PBMC to 
North American GS aqueous extracts. Human PBMC were stimulated with 1 µg/mL of 
aqueous extract and increasing concentrations of the indicated deglycosylated 
ginsenoside for 20 h. (A) C-Mc1 ( ), C-K (▲) and C-Mc (▼), (B) C-O (), C-Y (●) and 
Gyp LXXV (mixture) (), (C) Gyp XVII (mixture) ( ), Gyp LXXV (pure) ( ) and 
Gyp XVII (pure) ( ), (D) F2 ( ), PPD ( ), Rg3 ( ) and Rh2 ( ). Levels of IL-1β in 
culture supernatants were measured by ELISA. Data represent mean and standard 
deviation of three independent experiments performed in triplicate. Differences between 
responses to aqueous extract and aqueous extract with increasing concentrations of 
ginsenoside were significantly different as determined by one-way ANOVA ***: (P < 
0.001). 
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Figure 3.6 
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Figure 3.6. – Deglycosylated ginsenosides do not antagonize the IL-1β response of 
PBMC to North American GS polysaccharide extracts. Human PBMC were 
stimulated with 1 µg/mL of polysaccharide extract and increasing concentrations of the 
indicated deglycosylated ginsenoside for 20 h (A) C-Mc1 ( ), C-K (▲) and C-Mc (▼), 
(B) C-O (), C-Y (●) and Gyp LXXV (mixture) (), (C) Gyp XVII (mixture) ( ), Gyp 
LXXV (pure) ( ) and Gyp XVII (pure) ( ), (D) F2 ( ), PPD ( ), Rg3 ( ) and Rh2  
( ). Levels of IL-1β in culture supernatants were measured by ELISA. Data represent 
mean and standard deviation of three independent experiments performed in triplicate. 
Differences between responses to polysaccharide extract and polysaccharide extract with 
increasing concentrations of ginsenoside were significantly different as determined by 
one-way ANOVA ***: (P < 0.001). 
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Figure 3.7 
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Figure 3.7. – Deglycosylated ginsenosides antagonized the enhanced IL-6 response of 
PBMC mediated by the North American aqueous GS extract and LPS. Human 
PBMC were stimulated with 0.1 µg/mL of LPS and either 0.5 µg/mL of the indicated 
deglycosylated ginsenoside or 1 µg/mL of an aqueous extract, or both for 20 h. Levels of 
IL-6 in culture supernatants were measured by ELISA. Data represent mean and standard 
deviation of two independent experiments performed in triplicate. Differences between 
responses to LPS and a ginsenoside or LPS, a ginsenoside and an aqueous extract were 
significantly different as determined by two-way ANOVA ***: (P < 0.001).  
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Figure 3.8 
 
 
 
 
 
 
 
 
 
 
 
99 
 
Figure 3.8. – Deglycosylated ginsenosides did not antagonize the IL-6 response of 
PBMC to North American GS polysaccharide extracts and LPS. Human PBMC were 
stimulated with 0.1 µg/mL of LPS and either 0.5 µg/mL of the indicated deglycosylated 
ginsenoside or 1 µg/mL of a polysaccharide extract, or both for 20 h.  Levels of IL-6 in 
culture supernatants were measured by ELISA. Data represent mean and standard 
deviation of two independent experiments performed in triplicate.  
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To further corroborate the antagonism of biologically active ginsenoside on the response 
to North American GS extracts, we investigated their effects on the activation of T cells 
by SEE. When PBMC were stimulated with SEE, a high IL-2 response was detected (Fig. 
3.9). In the presence of the aqueous GS extract there was a decrease in IL-2 production as 
we have previously reported 20. Alternatively, when PBMC were treated with SEE in the 
presence of the aqueous GS extract and C-Mc1, C-K, C-Mc, C-O, C-Y, Gyp XVII 
(mixture), Gyp LXXV (mixture), Gyp XVII (pure), PPD and Rg3 the IL-2 response was 
restored to the levels seen with SEE alone (Fig. 3.9). Again, this antagonism was not 
observed for the North American GS polysaccharide extract except for Gyp XVII 
(mixture and pure) (Fig. 3.10). Together, our data indicate that biologically active 
ginsenosides act as an antagonist of the North American GS aqueous extract.  
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Figure 3.9 
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Figure 3.9. – Deglycosylated ginsenosides antagonize the effect of North American 
GS aqueous extracts on the IL-2 response of PBMC. Human PBMC were stimulated 
with 10 µg/mL of SEE and either 0.5 µg/mL of an indicated deglycosylated ginsenoside 
or 1 µg/mL of an aqueous extract, or both for 20 h. Levels of IL-2 in culture supernatants 
were measured by ELISA. Data represent mean and standard deviation of two 
independent experiments performed in triplicate. Differences between responses to SEE 
and a ginsenosides or SEE, a ginsenoside and an aqueous GS extract were significantly 
different as determined by two-way ANOVA *: (P < 0.05), **: (P < 0.01), ***: (P < 
0.001). 
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Figure 3.10 
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Figure 3.10. – Deglycosylated ginsenosides did not antagonize the IL-2 response of 
PBMC to North American GS polysaccharide extracts and SEE. Human PBMC were 
stimulated with 10 µg/mL of SEE and either 0.5 µg/mL of an indicated deglycosylated 
ginsenoside or 1 µg/mL of an polysaccharide extract, or both for 20 h. Levels of IL-2 in 
culture supernatants were measured by ELISA. Data represent mean and standard 
deviation of three independent experiments performed in triplicate. Differences between 
responses to SEE and a ginsenosides or SEE, a ginsenoside and an aqueous GS extract 
were significantly different as determined by two-way ANOVA *: (P < 0.05), **: (P < 
0.01), ***: (P < 0.001). 
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3.6 Discussion  
Our study is a comprehensive look at the immunomodulatory capacity of 11 processed 
and biologically active pure ginsenosides and two biologically active ginsenoside 
mixtures (Gyp LXXV and Gyp XVII). Our results show that these ginsenosides appear to 
have minimal pro-inflammatory effects. More importantly they can act as antagonists for 
North American GS aqueous extracts, partially blocking the effects of these cytokines on 
PBMC and the effects of these extracts on the innate (LPS) and adaptive (superantigen) 
immune responses.  
Overall, biologically active ginsenosides antagonize the properties of aqueous but not of 
polysaccharide GS extracts. The differential antagonism of the two extracts may be due 
to the fact that the higher potency of polysaccharides in the polysaccharide extract as 
compared to the aqueous extract that also contains ginsenosides and other compounds. 
However, based on the data that the aqueous extract can be antagonized by ginsenosides 
but the polysaccharide extract cannot be antagonized, leads to the idea that the 
antagonism of GS polysaccharide by ginsenosides is an example of competitive 
antagonism. This is because competitive antagonism can be overcome by increasing the 
concentration of the agonist 22; in this case the GS derived polysaccharides.  The degree 
of antagonism varies greatly between the different ginsenosides, suggesting that certain 
single, highly purified ginsenosides may have a higher affinity for the receptor than other 
ginsenosides. Alternatively, the observed antagonism may be due to an antagonistic 
effect of signalling molecules downstream of the receptors for ginsenosides and 
polysaccharides.  
The antagonism revealed here may help to identify the receptors mediating GS immune 
effects. One potential candidate for ginsenosides is the glucocorticoid receptor, whose 
ligands are the steroid hormones cortisol and other glucocorticoid hormones 23-26. 
However, ginsenosides have also been shown to affect a variety of cell signalling 
pathways including the AMPK pathway 27-29 and this may potentially result in 
immunomodulation. Despite extensive research, the identification of a ginsenoside 
receptor and hence the mechanism of action of ginsenosides remains unknown. Similarly, 
the GS polysaccharide receptor and its mechanism of action are also unknown. GS 
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polysaccharides have been proposed to use TLR 2 and TLR 4 as receptors to mediate 
their effects 30, 31. Future studies may then focus on these and other receptors to assess the 
degree of antagonism of ginsenosides or other responses through these receptors. 
The antagonistic properties of each ginsenoside varied. This may be in part due to the 
structure of the ginsenosides and their ability to interact with their putative receptors. 
While the backbone of all ginsenosides is very similar, the attached sugar groups are 
what give each ginsenoside its unique properties. These sugar groups may be important 
for receptor affinity and could explain the variable effects of different ginsenosides. The 
inability to antagonize the polysaccharide GS extract is likely due to differences in the 
composition of the aqueous and polysaccharide North American GS extracts. GS extracts 
contain three major groups of immunomodulatory compounds: ginsenosides 15, 32, 33, 
polysaccharides 30, 34, 35 and polyacetylene compounds 36, 37. These three compounds are 
present in the unfiltered aqueous GS extract, where there is no treatment to preferentially 
remove specific compounds 19. In contrast, the polysaccharide extract is composed of 
only the polysaccharides from the aqueous extract and undergoes significant processing 
to remove other contaminants 19. Therefore, the preferential antagonism of the aqueous 
extract may be due to its lower concentration of polysaccharides or the variety of 
compounds present.  
The work presented here further defines the complex immunomodulatory nature of GS. 
Based on our results, we propose that ginsenosides are not the primary 
immunomodulatory component of GS. As we have previously shown, the immune 
modulatory properties of North American GS extracts are mostly recapitulated by high 
molecular weight polysaccharides. Aqueous extracts do contain these polysaccharides. 
The observation repeated here mostly that aqueous preparations of North American GS 
may have lower effects due to a high content of ginsenosides. In contract polysaccharide 
preparations may be more clinically beneficial and not susceptible to antagonism.  
In conclusion, we show that biologically active ginsenosides act as antagonists of North 
American GS aqueous extracts. These results may be important to optimize the use of 
North American GS preparations tailors to specific immune modulatory properties.  
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4 Discussion 
4.1 Overview of Experimental Results  
4.1.1 Specific Aim One: To establish the effects of ginseng extracts on 
innate and adaptive immune responses of human PBMC. 
To investigate the immunomodulatory effects of North American ginseng extracts on 
human PBMC, induction of pro-inflammatory (IL-6, IL-1β, TNF-α) and anti-
inflammatory (IL-10) cytokines were used as readouts. Treatment of PBMC with the 
aqueous and polysaccharide ginseng extracts as well as COLD-FX® resulted in 
significant up-regulation of the aforementioned cytokines, when compared to cytokine 
induction by the ethanol ginseng extract.  All cytokines were produced in a dose-
dependent manner. In order to ensure that the observed cytokine production was not 
unique to the ginseng produced at a single farm, the three different ginseng extracts were 
produced from ginseng harvested from seven different farms across south western 
Ontario to determine cytokine production. Similar trends were observed between the 
extracts of all seven farms. Ginseng aqueous and polysaccharide extracts as well as 
COLD-FX® induce complex immune responses characterized by significant induction of 
pro-inflammatory cytokines but also the induction of the anti-inflammatory cytokine IL-
10. The differential production of these cytokines by the three different North American 
ginseng extracts may be due to the quantities of the major immunomodulatory 
compounds in each of the extracts. It appears that extracts that contain high 
concentrations of ginseng polysaccharides (e.g. the aqueous and polysaccharide extracts) 
induced higher cytokine production than the highly ginsenoside based ethanol extract.  
Polymyxin B treatment of the aqueous, polysaccharide and ethanol ginseng extracts, as 
well as COLD-FX®, was used to determine if the extracts were contaminated with LPS. 
Polymyxin B treatment did not affect the induction of pro-inflammatory cytokine 
production by ginseng extracts. Therefore, the induction of pro-inflammatory cytokines 
was based on components of the ginseng extracts and not LPS contamination.  
To determine the IL-6 contribution of monocytes to the total amount of IL-6 produced by 
PBMC, two monocyte subsets were isolated. CD14+ and CD14+CD16+ monocytes, were 
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isolated from PBMC and treated with the aqueous or polysaccharide ginseng extracts or 
COLD-FX®. There was no significant difference in IL-6 production of the two monocyte 
populations after treatment with the aqueous or polysaccharide ginseng extracts or 
COLD-FX®. However, there was a significant difference in the IL-6 production of PBMC 
when compared to CD14+ and CD14+CD16+ monocytes treated with the aqueous and 
polysaccharide ginseng extracts. The difference in IL-6 production between PBMC and 
the two isolated monocyte populations was not significantly different when treated with 
COLD-FX®. Therefore, the complex mixture of polysaccharides present in the aqueous 
and polysaccharide extracts is able to activate multiple cell types including monocytes. 
While the single polysaccharide family present in COLD-FX® only activates monocytes 
to produce IL-6.  
To characterize the effects of ginseng extracts and COLD-FX® on the innate immune 
system, LPS stimulation was used. None of the aqueous, polysaccharide or ethanol 
ginseng extracts nor COLD-FX® had an effect on the induction of IL-6 in response to 
LPS. This trend was observed across different concentrations of LPS as well as ginseng 
extracts and COLD-FX® and therefore it is not likely to be due to a saturation of the 
responses. 
In order to further characterize the effect of ginseng extracts on immune responses, the 
adaptive T cell response to SEE was used. PBMC treated with SEE and the aqueous or 
polysaccharide ginseng extracts significantly decreased IL-2 production compared to 
PBMC treated with SEE. The ethanol ginseng extract and COLD-FX® however, did not 
significantly change the SEE induced IL-2 production of PBMC. These trends were again 
observed under a variety of concentrations of extracts, COLD-FX® and SEE. Based on 
our results it appears that North American ginseng aqueous and polysaccharide extracts 
as well as COLD-FX® decreased the adaptive immune response to SEE, while having no 
effect on innate immune responses to LPS.  
The results reported in this aim were consistent across the seven different ginseng farms 
tested. Upon confirmation of these results, only ginseng extracts from farm 3 were used 
in further investigations. 
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4.1.2 Specific Aim Two: To define the transcriptional profile induced 
by the aqueous ginseng extract. 
In order to determine the transcriptional profile of PBMC treated with the aqueous 
ginseng extract, microarray analysis was performed for two independent donors. After 
exclusion of genes with less than a two-fold change in mRNA expression as compared to 
unstimulated PBMC, 104 genes were commonly up regulated and 53 genes were down-
regulated. A bioinformatics analysis of these genes revealed a transcriptional profile of 
immunomodulation. Specifically, IFN-γ gene was the most up-regulated gene, coding for 
the primary Th1 cytokine. Formyl peptide receptor 3 (FPR3) was the most down-
regulated gene. A large number of the regulated genes coded for chemokines, cytokines 
or were genes required for proper immune function. These results were replicated in 
genetically unrelated donors. In order to compare the modulation of genes in each donor, 
heat mapping was used. There were strong similarities in heat map profiles between these 
donors, indicating that the profile of immunomodulation was similar in both donors.  
To determine the effects of modulating the top 20 up-regulated genes, Ingenuity Pathway 
Analysis (IPA) was used. IPA uses software to determine the biological pathways most 
perturbed by these genes forming a network of interactions. In doing this, there was 
strong inferred modulation of the MAPK (ERK-1/2), PI3K, p38 and NF-κB pathways in 
response to treatment of PBMC with the aqueous ginseng extract. Further analysis of this 
network also strongly represents the dominance of cytokines, chemokines, receptors and 
signalling pathways involved in a Th1 immune response.  
Microarray analysis showed increased transcript levels of IFN-γ, IL-12p40, IL-12p70 and 
IL-23 after treatment of PBMC with the aqueous ginseng extract. ELISA was used to 
determine the effects of the polysaccharide and ethanol ginseng extracts and COLD-FX® 
on the induction of these cytokines by PBMC. The aqueous ginseng extract induced 
significant up-regulation of all four cytokines, IFN-γ, IL-12p40, IL-12p70 and IL-23 
compared to an un-stimulated control. However, the polysaccharide ginseng extract 
induced significant amounts of IFN-γ IL-12p40 and IL-23, as compared to the ethanol 
ginseng extract that only produced significant amounts of IL-12p40. COLD-FX® did not 
induce production of IFN-γ, IL-12p40, IL-12p70 and IL-23 above levels of the baseline 
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control. Alternatively, CD14 was shown in the microarray to be down-regulated by a fold 
change of between 3.3 and 4.2. The expression of surface CD14 was significantly down 
regulated in PBMC treated with the aqueous ginseng extract and COLD-FX® when 
compared to an un-stimulated PBMC control. Expression of CD14 was measured by flow 
cytometry.  
 
4.1.3 Specific Aim Three: To perform a preliminary isolation and 
characterization of the active immunomodulatory compounds of 
ginseng.  
The nature of the aqueous and polysaccharide ginseng extracts is that they are composed 
of many different compounds, which is especially true for the aqueous extract that 
contains both a variety of ginsenosides as well as many polysaccharides. Therefore, in 
order to determine which of the many compounds in these extracts were responsible for 
the immunomodulatory properties, fractionation of the extracts was required. When the 
aqueous and polysaccharide extracts were fractioned based on molecular weight, the only 
fraction that recapitulated the induction of IL-6 was the greater than 100 kDa fraction. To 
confirm this result all fractions as well as the aqueous and polysaccharide ginseng extract 
were tested to compared the effects of the fractions and extracts on the SEE response. 
Similar to previous results, only the greater than 100 kDa fraction down-regulated the 
SEE induced IL-2 production of PBCM to the same magnitude as the aqueous and 
polysaccharide North American extracts.  
Ginsenosides, unique saponin molecules found only in some species of ginseng have 
historically been known as the active ingredients of ginseng. However, since 
ginsenosides have a molecular weight less then 20 kDa, the notion of ginsenosides as the 
immunomodulatory compounds of ginseng conflicted with our previous results. To 
determine the effects of ginsenosides on immunomodulation, 11 purified, biologically 
active ginsenosides and two ginsenoside mixtures were obtained. The majority of these 
ginsenosides did not induce IL-1β production in PBMC. Only C-Y, C-Mc and Gyp 
LXXV (pure) induced the pro-inflammatory cytokine IL-1β above baseline controls. This 
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is compared to almost half of the ginsenosides that induced significant amounts of IL-6 
production in PBMC, including C-Y, C-Mc, Gyp LXXV (pure), C-O and Gyp XVII 
(mixture). 
These 13 ginsenosides were also tested for their immunomodulatory capacity of the LPS 
and SEE induced responses of PBMC. PBMC were co-stimulated with each of the 
ginsenosides and LPS using IL-6 production as a marker of activation. All 13 
ginsenosides tested decreased IL-6 production in response to LPS. However, when 
PBMC were stimulated with SEE and each of the ginsenosides there was no biologically 
relevant difference in IL-2 production.  
Considering the opposing results that ginsenosides decrease the LPS response while the 
aqueous extract containing ginsenosides had no effect on the LPS response, there 
appeared to be a possible antagonistic effect of the ginsenosides and polysaccharides in 
the aqueous extract. To determine if there were any antagonistic effects of 
polysaccharides or ginsenosides, PMBC were co-stimulated with ginsenosides and the 
aqueous or polysaccharide ginseng extracts. All of the 13 ginsenosides tested antagonized 
the induction of IL-1β in PBMC co-treated with the aqueous ginseng extract. 
Alternatively, none of the 13 ginsenosides antagonized IL-1β production by PBMC co-
treated with the polysaccharide ginseng extract.  
The antagonism of the aqueous extract prompted the study of ginsenosides effect on the 
response of PBMC treated with the aqueous or polysaccharide ginseng extracts and LPS. 
When PBMC were stimulated with LPS, the aqueous ginseng extract and each of the 
ginsenosides, all of the ginsenosides significantly decreased IL-6 production in PBMC 
except Gyp LXXV (mixture), Gyp XVII (mixture), Gyp LXXV (pure). Similar to 
previous data, PBMC treated with LPS, the polysaccharide ginseng extract and each of 
the ginsenosides resulted in no significant decrease in IL-6 production when compared to 
PBMC treated with LPS and the aqueous ginseng extract.  
Finally, the antagonistic effect of ginsenosides on the aqueous and polysaccharide 
ginseng extracts was also characterized using the response of PBMC to SEE. When 
PMBC were treated with SEE, the aqueous ginseng extract and each of the ginsenosides, 
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all of the ginsenosides except Gyp LXXV (pure), F2 and Rh2 resulted in increased IL-2 
production when compared to PBMC treated with SEE and the aqueous ginseng extract. 
Alternatively, when PBMC were treated with SEE, the polysaccharide ginseng extract 
and Gyp XVII (mixture) or Gyp XVII (pure) there was a significant increase in IL-2 
production compared to PBMC treated with SEE and the polysaccharide extract. All the 
rest of the ginsenosides had no effect on IL-2 production induced by SEE and the 
polysaccharide extract. If the ginsenosides are antagonizing the ginseng polysaccharides 
in the aqueous extract, than there would be a clinical benefit to using preparations of 
single types of ginseng derived compounds based on the desired effect.  
 
4.2 Model of function:  
4.2.1 Ginseng induces a Th1 transcriptional profile  
Ginseng has been thought to have an immunomodulatory role for hundreds of years but 
only recently has this been properly and thoroughly documented. Ginseng has an 
immunomodulatory role on human primary cells in vitro, through the induction of a Th1 
response as determined by transcriptional profiling. This transcriptional profile is likely 
the result of modulation of signals mediated by the MAPK (ERK-1/2), PI3K, p38 and 
NF-κB pathways, as compounds of these pathways were among the 20 most up-regulated 
genes identified by the microarray analysis. These pathways have been extensively 
documented in the literature to be altered in a variety of immunomodulatory effects 
including decreasing ischemic reperfusion injury 1-3, tumor killing 4 and preferential 
apoptosis of cancer cells 5. Activation of MAPK (ERK-1/2), PI3K, p38 and NF-κB 
pathways has also been shown to induce pro-inflammatory cytokines such as IL-6 and 
TNF-α that is consistent with previous results from our lab and others 6-8.  
CD4+ Th1 cells are characteristically large producers of IFN-γ and are responsible for 
activating macrophages and the differentiation of CD8+ T cells into cytotoxic cells. 
Transcriptional analysis of PBMC stimulated with the North American aqueous ginseng 
extract revealed an up-regulation of IFN-γ mRNA by a fold change between 53.2-55.9 
above control. The induction of IFN-γ was also observed at the protein level by the 
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aqueous and polysaccharide ginseng extracts. However, when PBMC are co-stimulated 
with those extracts and SEE there was a significant decrease in IL-2 production. 
Together, these results imply that the production of IFN-γ is likely not coming from T 
cells and is instead being secreted by NK cells, the other major producer of IFN-γ. 
Furthermore, the induction of Th1 immune responses in general, coupled with the 
induction of pro-inflammatory cytokines is likely the mechanism used to induce many of 
the reported immune enhancing properties of ginseng extracts and COLD-FX®.  
While the evidence for a Th1 immune response induced by North American ginseng 
extracts is clear, there are reports in the literature that ginseng also induces of a Th2 
response.  The reported Th2 immune response is usually based on the observation of 
induction of IL-10, IL-4 or IL-5 9-11. Based on microarray analysis, ginseng extracts did 
not affect the regulation of these cytokines by greater than a two-fold change. However, 
our results did show an induction of IL-10 at the protein level. This induction of IL-10 
may explain why none of the ginseng extracts had an effect on the LPS response, as IL-
10 is known to suppress macrophage function 12. The presence of IL-10 may also have a 
modulatory role in the strong induction of pro-inflammatory cytokines 12.  
North American ginseng induces an immunomodulatory affect by altering the 
transcriptional profile of susceptible cells resulting in the promotion of a Th1 response. 
This response is likely mediated by modulation of the MAPK (ERK-1/2), PI3K, p38 and 
NF-κB which induces the characteristic production of IFN-γ and pro-inflammatory 
cytokines. The production of IFN-γ is likely by NK cells and results in the activation of 
macrophages, and removal of intracellular pathogens and dying cancer cells. Ginseng 
also appears to induce an IL-10 response although this was not observed by microarray 
analysis and may serve to modulate the strong pro-inflammatory responses observed 
through feedback mechanisms.  
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4.2.2 High molecular weight polysaccharides are the Active 
Immunomodulatory Compounds of Ginseng 
The ginseng aqueous extract is a complex mix of ginsenosides and polysaccharides, both 
of which have been shown to be immunomodulatory. The polysaccharide ginseng extract 
is a purified solution of only the polysaccharides present in the aqueous ginseng extract. 
Across all of the bioassays completed, the aqueous and polysaccharide ginseng extracts 
induced similar responses. The ethanol extract, which is a ginsenoside rich extract, 
appears to have very little if any immunomodulatory capacity. From this it can be 
inferred that the polysaccharides in the aqueous extract are the strongest 
immunomodulatory compounds in the aqueous ginseng extract.  
To further characterize the immunomodulatory compounds of ginseng, differential 
fractionation was used to separate the ginsenosides and polysaccharides of the aqueous 
and polysaccharide extracts. Ginsenosides are low molecular weight compounds, 
typically less than 20 kDa while polysaccharides usually range from 50-150 kDa 13. Only 
compounds with a molecular weight greater than 100 kDa induced a similar production 
of IL-6 from PBMC as the North American ginseng aqueous or polysaccharide extracts. 
These results are consistent with the immunomodulatory compounds being the 
polysaccharides and not the ginsenosides.  
There is a clear difference between a polysaccharide extract composed of a complex 
mixture of polysaccharides and poly-furanosyl-pyranosyl-saccharides, a single 
polysaccharide family isolated from an aqueous ginseng extract. COLD-FX®, is 
composed of over 80% poly-furanosyl-pyranosyl-saccharides. Similar to the 
polysaccharides in the polysaccharide ginseng extract, poly-furanosyl-pyranosyl-
saccharides are also isolated from a North American aqueous ginseng extract. However, 
there is a difference in the modulatory effect of the polysaccharide ginseng extract and 
COLD-FX®. For example, when comparing the IL-6 production of CD14+ monocytes, 
CD14+CD16+ monocytes and PBMC treated with the aqueous or polysaccharide ginseng 
extract, both populations of monocytes produced significantly less IL-6 than PMBC. 
However, COLD-FX® induced a similar production of IL-6 regardless of cell type. 
119 
 
Therefore, the variety of compounds in the polysaccharide extract induces a broader 
range of cell populations to secrete the pro-inflammatory cytokine IL-6 than COLD-FX®. 
The effects of ginseng on a variety of immune responses has been well characterized in 
the literature. However there is complete lack of knowledge on a well defined receptor. 
Other plant polysaccharides have been shown to bind to CD14 and TLR-4 14, 15, but there 
is no clear evidence whether or not ginseng polysaccharides do as well. Without knowing 
the receptor of ginseng polysaccharides, it is difficult to determine why COLD-FX® 
appears to stimulate only the monocyte cell population of PBMC, while the 
polysaccharide extract stimulates other cell populations also. It could be because the 
polysaccharides in the North American polysaccharide ginseng extract are ligands for 
multiple receptors, some of which that are not found on monocytes.  
 
4.2.3 The Role of Ginsenosides in Immunomodulation 
While ginseng polysaccharides clearly drive the production of pro-inflammatory 
cytokines and many other immune responses, it was possible that ginsenosides could also 
have an immunomodulatory role. 13 physiologically active ginsenosides were tested for 
their ability to induce pro-inflammatory cytokines, their effects on the innate immune 
response to LPS and their effects on the adaptive T cell response to SEE. All 13 of the 
ginsenosides decreased the production of IL-6 by PBMC in response to LPS stimulation. 
These results were contradictory to similar experiments using the ethanol extract, which 
is known to contain only ginsenosides 13. This may be because the ethanol extract is 
composed of all of the ginenosides present in the ginseng root and the concentration of 
any given ginsenoside depends on its predominance in the root. Therefore, the 
concentration of each single ginsenoside in the ethanol extract may be too small to have 
an effect on PBMC treated with LPS.  
Another difference between the purified ginsenosides and the ethanol extract is that 
purified ginsenosides were deglycosylated by bacteria into their active form. This mimics 
the conditions of being ingested, processed and absorbed in the gut. Therefore, the 
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ginsenosides in the ethanol extract are much larger and contain extra sugar groups which 
may alter receptor-binding affinity or prevent receptor binding all together. However, the 
effect of the larger sized ginsenosides and the presence of excess sugars on receptor 
affinity and binding cannot be determined as there is no known ginsenoside receptor.  
Ginsenosides have been proposed to bind the glucocorticoid receptor, however the 
evidence is not robust 16-18. Typically, cortisol and other glucocorticoid hormones are the 
ligands of the glucocorticoid receptor. However, due to the similar structure of 
ginsenosides to these steroid hormones, ginsenosides have also been proposed to bind to 
glucocorticoid receptors. The evidence for the glucocorticoid receptor as the receptor for 
ginsenosides is weak and further research is required. Ginsenosides have also been shown 
to affect the signalling of a variety of signalling pathways including the AMPK pathway 
19-21
. This signalling pathway may also be involved in the immunomodulation by 
ginsenosides.  
 
4.2.4 Ginsenosides Antagonize the effects of the North American 
Ginseng Aqueous Extract 
The immunomodulatory roles of ginsenosides and polysaccharides are very different. Our 
data indicate that ginsenosides antagonize some of the modulatory effects of 
polysaccharides in North American aqueous ginseng extracts. The antagonistic effect of 
ginsenosides on the aqueous extract is clear. However, antagonism of the polysaccharide 
extract is more dependent on the response and ginsenoside in question. The obvious 
difference between the aqueous and polysaccharide extract is their composition. The 
polysaccharide extract is composed of only the polysaccharides of the aqueous ginseng 
extract, while the aqueous extract contains ginsenosides and other compounds. When 
equal concentrations of both extracts are added, PBMC receiving the polysaccharide 
extract would be receiving a greater amount of polysaccharide than PBMC treated with 
the aqueous extract. Therefore the lack of antagonism by ginsenosides of the 
polysaccharide extract may be due to a saturating effect of the polysaccharide.  
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The mechanism of the antagonism of ginseng polysaccharides by ginsenosides cannot be 
determined without knowing the receptor for both compounds. The receptors may signal 
through different biochemical pathways which interact downstream of activation to 
inhibit the signalling of one pathway over the other. This is the most likely explanation 
for the antagonism, as the antagonism of the aqueous ginseng extract does not appear to 
be dose dependent. Thus, it is not likely that ginsenosides and ginseng derived 
polysaccharides share a receptor.  
 
4.3 Future directions:  
4.3.1 To analyze in depth the microarray results  
Microarray analysis of PBMC treated with the aqueous ginseng extract produced 104 up-
regulated genes and 53 down-regulated genes, each of possible importance to ginseng 
immunomodulation. These results provide a complex picture of immunomodulation by 
ginseng and are the basis for further investigation. For example, the down-regulation of 
TGF-β, an important anti-inflammatory cytokine that plays a role in T cell differentiation 
may be important in determining the differentiation of T cells into lineages other then 
Th1. TGF-β also induces would healing and scar formation, therefore its down regulation 
will inhibit these aspects and may induce chronic inflammation. Thus further study is 
required to determine the effects of down-regulating TGF-β in the context of such large 
induction of pro-inflammatory cytokine and the effect on chronic inflammation. This will 
also be important when considering the context and duration of North American ginseng 
use. There is also a series of chemokine receptors and other receptor molecules that have 
been identified as being down-regulated by microarray analysis.  These receptors may be 
valuable in further understanding the exact role of North American ginseng extracts and 
purified compounds in cell recruitment and immune responses.  
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4.3.2 To identify the receptor of ginsenosides and ginseng 
polysaccharides 
A major block in the progress of ginseng research is that there is no concrete evidence of 
a receptor for the ginsenosides or ginseng polysaccharides. While the glucocortiod 
receptor has been proposed as a receptor for ginsenosides, the evidence is not complete. 
Identifying a receptor would allow for further understanding of the antagonism of 
polysaccharides by ginsenosides, which could be due to cross talk in biochemical 
signalling pathways downstream of the receptor.  
In order to determine the receptor of ginseng polysaccharides, it is first important to 
determine the structure of each of the polysaccharides in the polysaccharide ginseng 
extract using nuclear magnetic resonance spectroscopy. Molecular analysis can be done 
based on the structure of the ligand polysaccharides to determine possible receptors on 
responding cells such as T cells, monocytes and NK cells. Following this, these receptors 
could be knocked out using cell lines of specific immune cells, or they could be blocked, 
depending on the receptor. If the ginseng receptor is knocked out or blocked successfully 
then treatment with the ginseng polysaccharide extract should not induce cytokine 
production or changes in any of the signalling pathways of the cell.  
  
4.4 Ginseng in disease:  
4.4.1 Ginseng in Cancer 
Ginseng has a broad range of effects on many cell-signalling cascades and therefore has 
been investigated as an anti-cancer agent. Ginseng treatment of many human cancers 
including hepatocellular carcinoma, lung carcinoma, breast cancer and cervical cancer 
has been shown to be beneficial 22-25. For example, ginsenosides have been shown to 
decrease tumor invasion and metastasis, decrease tumor weight and volume and inhibit 
cell proliferation 22, 24, 26. In a gastric cancer model, treatment with the ginsenoside C-K 
induced apoptosis through a Bid-mediated mitochondrial pathway 27.  Similarly, when the 
same gastric cancer cells were injected into nude mice, C-K treatment of those mice 
123 
 
decreased tumor formation 27. C-K is not the only ginsenoside however to have anti-
cancer effects. Rg3 has been shown to decrease tumor weight and volume by 30% in lung 
carcinoma cells 23. Rh2 also induced mitochondria mediated cell death by the up-
regulation of the pro-apoptotic factors Bak, Bax and Bim while down-regulating the anti-
apoptotic factors Bcl-2, Bcl-xL and Mcl-1 28. Finally, using human colon cancer cells, an 
aqueous ginseng extract as well as its purified ginsenoside and polysaccharide 
components all decreased cell proliferation 29. There appears to be significant evidence 
that ginsenosides mediate the apoptosis of cancer cells through mitochondrial mediated 
apoptosis 27, 28, 30. Ginsenosides have been shown to arrest cell growth in the G0/G1 phase 
29, 31
. These results indicate that purified components of ginseng as well as ginseng 
extracts may be a useful tools in the fight against cancer.  
 
4.4.2 Ginseng in Diabetes 
Ginseng has been well studied with respect to its hypoglycemic effects with promising 
results. There have even been clinical trials completed based on these results, however 
the lack of standardization of ginseng has resulted in the failure of such trials. 
Nonetheless, ginseng was shown to decrease blood glucose when given 40 minutes prior 
to a meal in both control and patients with diabetes mellitus 32. Ginseng has also been 
shown to decrease insulin resistance and fasting blood glucose in diabetes mellitus 33. A 
ginseng aqueous extract has also been shown to increase insulin secretion from β cells 
and prevent β cell apoptosis 34. This was proposed to occur through inhibition of the 
mitochondrial protein uncoupling protein 2 (UCP-2) which increases ATP and the anti-
apoptotic factor Bcl-2 34. In addition to modulating UCP-2 and Bcl-2, under high glucose 
conditions, ginsenosides Rb1, Rg3 and Rb2 have been shown to decrease the 
phosphorylation of JNK, p38 and p42/p44 MAPK resulting in a protective effect against 
diabetic nephrology 35. These results show that ginseng plays a complex role in mediating 
diabetic β cell apoptosis, as well as moderating blood glucose.  
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4.5 Conclusions: 
Ginseng was thought to be immunomodulatory for hundreds of years before science 
actually provided any evidence to support this claim. However, the majority of ginseng 
research has been done using neoplastic cell lines that are not representative of the variety 
of cells involved in a human immune response. The work presented in this thesis 
provides evidence of immunomodulation in human PBMC by ginseng polysaccharides 
and ginsenosides as well as an aqueous and polysaccharide North American ginseng 
extracts.  
Initially, the induction of pro- and anti-inflammatory cytokines in PBMC by the aqueous 
and polysaccharide ginseng extracts was confirmed. There was significantly less cytokine 
production induced by the ethanol ginseng extract. This trend was also observed in 
response to SEE stimulation of adaptive T cell responses. The aqueous and 
polysaccharide ginseng extracts significantly reduced the IL-2 production in PBMC while 
the ethanol ginseng extract had no effect on IL-2 production. This immunomodulatory 
profile was confirmed at the transcriptional level by microarray analysis. Ginseng induces 
its immunomodulatory affects by altering gene transcription in susceptible cells resulting 
in a pro-inflammatory Th1 immune response characterized by the induction of IFN-γ. 
Finally, we have shown that the modulation of immune responses by ginseng 
polysaccharides and ginsenosides is different and that certain ginsenosides can 
antagonize polysaccharide-induced responses. Ginsenosides antagonize the induction of 
pro-inflammatory cytokines induced by LPS stimulation. They also antagonized the 
responses of the aqueous and to a lesser extent the polysaccharide ginseng extracts.  
Based on these results, we propose that ginseng induced immunomodulation results in a 
Th1 transcriptional signature mediated primarily by ginseng polysaccharide. The Th1 
profile is characterized by IFN-γ production by NK cells and the activation of MAPK 
(ERK-1/2), PI3K, p38 and NF-κB pathways. This profile is induced by the complex 
mixture of ginseng polysaccharides found in the aqueous and polysaccharide ginseng 
extracts. However, ginsenosides present in the aqueous extract decrease some of the 
immunomodulatory responses. Ginsenosides modulate immune response to LPS and SEE 
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in opposing ways as the ginseng polysaccharides. Further work is required to determine 
how ginsenosides antagonize the effects of ginseng polysaccharides.  
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